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The transcription factor, signal transducer and activator of transcription 3 (STAT3), has 
been implicated in protecting the heart from acute ischemic injury under both basal con-
ditions and as a crucial component of pre- and post-conditioning protocols. A number 
of anti-oxidant and antiapoptotic genes are upregulated by STAT3 via canonical means 
involving phosphorylation on Y705 and S727, although other incompletely defined post-
translational modifications are involved. In addition, STAT3 is now known to be present 
in cardiac mitochondria and to exert actions that regulate the electron transport chain, 
reactive oxygen species production, and mitochondrial permeability transition pore
opening. These non-canonical actions of STAT3 are enhanced by S727 phosphorylation. 
The molecular basis for the mitochondrial actions of STAT3 is poorly understood, but 
STAT3 is known to interact with a critical subunit of complex I and to regulate complex 
I function. Dysfunctional complex I has been implicated in ischemic injury, heart failure, 
and the aging process. Evidence also indicates that STAT3 is protective to the heart 
under chronic stress conditions, including hypertension, pregnancy, and advanced age. 
Paradoxically, the accumulation of unphosphorylated STAT3 (U-STAT3) in the nucleus 
has been suggested to drive pathological cardiac hypertrophy and inflammation via 
non-canonical gene expression, perhaps involving a distinct acetylation profile. U-STAT3 
may also regulate chromatin stability. Our understanding of how the non-canonical
genomic and mitochondrial actions of STAT3 in the heart are regulated and coordinated 
with the canonical actions of STAT3 is rudimentary. Here, we present an overview of 
what is currently known about the pleotropic actions of STAT3 in the heart in order to 
highlight controversies and unresolved issues.
 
 
Keywords: mitochondria, U-STAT3, complex i, myocardial infarction, cardiac hypertrophy, heart failure, peripartum 
cardiomyopathy, ischemic pre- and post-conditioning
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iNTRODUCTiON
Signal transducer and activator of transcription 3 (STAT3) 
is both a transcription factor and signaling molecule that 
modulates mitochondrial function (1–5). In the heart, both the 
protein levels and activation status of STAT3 are dynamic, as is 
its subcellular distribution. In this context, STAT3 acts as a sensor 
of both acute and chronic stress so as to implement protective 
measures against oxidative damage or pro-death signaling, or 
perhaps ensure structural stability of microtubules or chromatin 
(1). Notably, STAT3 levels and activity in the heart are reported 
to be reduced with heart failure, aging, and diabetes (1, 6–11). In 
the nucleus, STAT3 as a transcription factor has both canonical 
actions, very often in association with NF-κB, which are initiated 
by external stimuli and non-canonical actions that result from 
its accumulation due to a STAT3-induced STAT3 circuit (1). 
STAT3’s non-canonical genomic actions may include as well 
modulation of chromatin structure (1). In addition, STAT3 has 
non-genomic (non-canonical) actions involving regulation of 
mitochondrial function and integrity. Our understanding of the 
interplay between the canonical and non-canonical genomic and 
non-genomic, actions of STAT3 within the stressed or diseased 
heart is still fairly basic (Figure 1).
Signal transducer and activator of transcription 3 is a tran-
scription factor that is activated by phosphorylation on a specific 
tyrosine residue (Y705) in cardiac myocytes by agonists that 
engage membrane receptors directly coupled to activation of Just 
Another Kinase (JAK) 1 or JAK2 tyrosine kinases (1–5). These 
agonists have pathophysiological importance and include the 
interleukin 6 (IL-6) family cytokines, such as IL-6 and leukemia 
inhibitory factor (LIF), tumor necrosis factor (TNF), interferon 
gamma (IFNγ), erythropoietin, and granulocyte-colony stimu-
lating factor (G-CSF). Y705 can also be phosphorylated by Src 
family kinases and tyrosine kinase bone marrow kinase on 
chromosome X (BMX) in cardiac myocytes (12–14), although the 
physiological significance of this is unclear. Mechanical stretch 
and pressure overload, but not volume overload, are reported 
to activate STAT3 in cardiac myocytes or the myocardium (13, 
15–22). Pressure overload-induced activation of STAT3 in the 
heart is mainly dependent on the autocrine/paracrine-release of 
IL-6 family cytokines, with a lesser contribution from local angio-
tensin II production (19–22). Angiotensin II activates STAT3 in 
cardiac myocytes and fibroblasts directly via the angiotensin II 
type 1 (AT1) receptor, which contains a JAK2 binding site in the 
C-terminus, as well as by upregulating expression of IL-6 family 
cytokines (23–25).
Besides functioning as a transcription factor STAT3 is 
now known to have poorly understood non-genomic actions 
in mitochondria that modulate respiration, reactive oxygen 
species (ROS) formation, and opening of the mitochondrial 
permeability transition pore (mPTP) (1, 4, 5). Overwhelming 
evidence supports the conclusion that STAT3 is important for 
the protection of the heart from acute ischemic stress by both 
genomic and non-genomic means (1). Although less well stud-
ied, STAT3 appears to be important for protection of the heart 
from chronic stress, such as pressure overload (17). We also 
observed that mice homozygous for a STAT3 S727A mutation 
that impairs both genomic and non-genomic actions exhibited 
cardiac dysfunction and evidence of cardiac myocyte necrosis 
at an early stage of angiotensin II-induced hypertension (26). 
In this review, we present an overview of the role of STAT3 in 
the heart in acute and chronic stress with a focus on unresolved 
issues and controversies.
Posttranslational Modifications of STAT3
Signal transducer and activator of transcription 3 is 770 
amino acids in length with six distinct domains (Figure  2). 
The coiled coil domain is involved in protein–protein interac-
tions, and the SH2 domain mediates STAT3 dimerization via 
intermolecular phosphorylated tyrosine–SH2 interactions. 
The amino acid sequence of STAT3 is highly conserved across 
species. STAT3 is modified at specific residues by a number of 
posttranslational modifications with functional consequences, 
most notably by phosphorylation and acetylation (Table 1). In 
addition, STAT3 can undergo s-nitrosylation, s-glutathionyla-
tion, di- or trimethylation, and mono-ubiquitination, although 
these modifications have not been specifically demonstrated in 
cardiac cells.
Abbreviations: ADMA, asymmetric dimethylarginine; AT1, angiotensin II 
type 1 receptor; Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra large; 
BMX, bone marrow kinase on chromosome X; BNIP3, BCL2/adenovirus E1B 19 
kDa protein-interacting protein 3; BRD4, bromodomain-containing protein 4; 
CamKII, Ca2+/calmodulin-dependent protein kinases II; c-FLIPL, cellular FLICE-
inhibitory protein, long; c-FLIPS, cellular FLICE-inhibitory protein, short; COX-2, 
cyclooxygenase-2; CRM1, chromosomal maintenance 1; DNMT1, DNA methyl 
transferase 1; EGFR, epidermal growth factor receptor; ERK1/2, extracellular-
signal-regulated kinase 1/2; ETC, electron transport chain; EZH2, enhancer of 
zeste homolog 2; GAS, interferon γ (gamma)-activated sequence; GRIM19, gene 
associated with retinoic-interferon-induced mortality 19; GSH, glutathione; 
HDAC1, histone deacetylase 1; HO-1, heme oxygenase 1; HP1, heterochromatin 
protein 1; HSP70, 70 kilodalton heat shock proteins; IFNγ, interferon gamma; 
IL-10, interleukin 10; IL-6, interleukin 6; JAK1/JAK2, just another kinase 1 or 
2; LIF, leukemia inhibitory factor; LIFR, leukemia inhibitory factor receptor; 
Mcl-1, myeloid cell leukemia-1; MHC, myosin heavy chain; MI, myocardial 
infarction; MLS, mitochondria localization sequence; mPTP, mitochondrial 
permeability transition pore; mTOR, mammalian target of rapamycin; ND1, 
NADH-ubiquinone oxidoreductase chain 1; ND3, (mitochondrially encoded) 
NADH dehydrogenase 3; NDUFA9, NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex subunit 9; NDUFS2, NADH dehydrogenase (ubiquinone) iron–sulfur 
protein 2, mitochondrial; NDUFS7, NADH dehydrogenase (ubiquinone) iron–
sulfur protein 7, mitochondrial; NDUFS8, NADH dehydrogenase (ubiquinone) 
iron–sulfur protein 8, mitochondrial; NES, nuclear export signal; NF-κB, nuclear 
factor kappa-light-chain-enhancer of activated B cells; NFAT, nuclear factor of acti-
vated t-cells; NLS, nuclear localization signal; PAR-1, protease-activated receptor 
1; PKC, protein kinase C; PPCM, peripartum cardiomyopathy; PRMT-1, protein 
arginine N-methyltransferase 1; PRMT2, protein arginine N-methyltransferase 
2; P-TEFb, positive transcriptional elongation factor; RISK, reperfusion injury 
salvage kinases; ROS, reactive oxygen species; SAFE, survivor activating factor 
enhancement; SDF-1α, stromal cell-derived factor 1 alpha; SET9, histone-lysine 
N-methyltransferase SET9; SH2, Src homology 2; SHP2, Src-homology 2 domain-
containing phosphatase 2; SIRT1, sirtuin 1; SIRT3, sirtuin 3; SOCS3, suppressor 
of cytokine signaling 3; SOD2, superoxide dismutase 2, mitochondrial; STAT3, 
signal transducer and activator of transcription 3; TAC, transverse aortic constric-
tion; TAD, transcription activation domain; TCA, tricarboxylic acid; TNF, tumor 
necrosis factor; TNFR-1, TNF receptor-1; Ube2g1, ubiquitin conjugating enzyme 
2g1; Ube2i, ubiquitin conjugating enzyme 2i; U-STAT, unphosphorylated STAT3.
FiGURe 2 | The six functional domains of STAT3. NTD, NH2-terminal domain; CCD, coiled coil domain; DBD, DNA-binding domain; LD, linker domain; SH2 
domain; TAD, transcription activation domain. The location of residues that are targets of various posttranslational modifications are indicated. Shown also are the 
two key regulatory residues by phosphorylation (Y705 and S727) within the TAD, as well as the novel site of phosphorylation T714 linked to transcriptional activity.
FiGURe 1 | The pleotropic actions of STAT3 in the heart and their interplay. STAT3 has both canonical and non-canonical actions that impact on the viability 
of the myocardium. Canonical STAT3-induced gene expression is associated with the upregulation of protective anti-oxidant and anti-apoptotic proteins, as well as 
maintaining the heath of the endothelium (e.g., by upregulating VEGF and SOD2). STAT3 induces its own expression leading potentially to the accumulation of 
unphosphorylated STAT3 (U-STAT3) in the nucleus, which has been associated with hypertrophy and inflammation. U-STAT3 may contribute to chromatin stability 
and gene suppression. STAT3 also directly suppresses/represses genes possibly by association with DNMT1 or HDACs. Loss of STAT3-mediated suppression of 
miR-199a-5p has been linked to endothelial dysfunction (center arrow). Gene repression may be important for mitochondrial biogenesis. STAT3 has direct 
mitochondrial actions that are poorly understood, but involve maintaining complex I/II activity and preventing mPTP opening. By sequestering STAT3 (perhaps 
involving redox modifications), mitochondria may reduce the nuclear transcriptional actions of STAT3. Canonical STAT3 signaling is likely important for mitochondrial 
health as well.
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Phosphorylation
Two sites of phosphorylation are important in canonical 
STAT3 activation and gene expression and are located in the 
C-terminal regulatory transcription activation domain or TAD 
(1). Phosphorylation of Y705 favors formation of parallel STAT3 
dimers that translocate to the nucleus and induce expression 
of certain genes containing an interferon γ (gamma)-activated 
sequence (GAS) element (TTCNNNGAA or variation thereof, 
TABLe 1 | Posttranslational modifications of STAT3.
Residue Domain Modification Function
R31 NTD Methylation • Attenuation of activation (27)
K49 NTD Dimethylation • Increased gene expression (28)
K49, K87 NTD Acetylation • Stable p300 association and gene expression (29, 30)
• HDAC1 association and nuclear export (termination of transcription) (31)
K87 NTD Acetylation • Sin3a-mediated transcription repression (32)
K97 NTD Mono-ubiquitination • Anti-apoptotic (BRD4-dependent) gene expression (33)
K140 CCD Dimethylation • Decreased gene expression (34)
K180 CCD Trimethylation • Increased Y505 phosphorylation/gene expression (35)
C259 CCD S-nitrosylation • Inhibits Y705 activation (phosphorylation) (36)
K685, K707, K709 SH2, TAD, TAD Acetylation • Regulation of Y705 phosphorylation (37)
• Inhibition of gluconeogenesis genes in liver (37)
K685 SH2 Acetylation • Stable dimer formation, DNA binding, transcription (38, 39)
• Interaction with DNMT1 and gene silencing (40, 41)
• U-STAT3-mediated gene expression (42)
Y705 TAD Phosphorylationa • Enhances dimerization and transcription/gene expression (1)
T714, S727 TAD Phosphorylation • Gene expression (43)
S727 TAD Phosphorylationa • Enhances gene expression (44)
• Mitochondrial actions (1, 4, 5, 45–48)
• Recruitment of tyrosine phosphatases/transcription termination (1, 49, 50)
CCD, coiled coil domain; NTD, N terminus domain; SH2, Src homology 2 domain; TAD, transcription activation domain. aDemonstrated in cardiac myocytes.
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such as a sis-inducible element, SIE) in their promoter (4, 23). 
The other site is S727, which is phosphorylated in the cytoplasm 
or nucleus by several serine/threonine kinases, including 
ERK1/2, protein kinase Cϵ (PKCϵ), PKCδ, ZIP kinase, mTOR, 
and CDK5 (1). In canonical STAT3 signaling S727 phosphoryla-
tion boosts the transcriptional activity of STAT3 by recruiting 
histone acetyltransferase p300/CBP (44). Phosphorylation of 
S727 is also important for interaction of STAT3 with GRIM19 
(complex I subunit B16.6 or NDUFA13) and uptake of STAT3 
by mitochondria (45, 51). The TAD of STAT3 has other func-
tions as well (1). Of note, recent evidence suggests that Y705 
phosphorylation may not be obligatory for canonical STAT3 
signaling and gene expression. In endothelial cells in response to 
simultaneous activation of the epidermal growth factor receptor 
(EGFR) and protease-activated receptor 1 (PAR-1), phospho-
rylation of STAT3 at T714 and S727 by glycogen synthase kinase 
(GSK) 3α and β was linked to gene expression in the absence of 
Y705 phosphorylation (43).
Acetylation
Acetylation of STAT3 on several lysine residues by p300 is an 
essential determinant of its transcriptional activity. Acetylation of 
K49 and K87 in the NH2 terminus is required for p300 binding and 
gene expression, although inducible DNA binding is not affected 
(29, 30). In addition, the NH2-terminal acetylation domain is 
required for HDAC1 binding and termination of transcription 
by STAT3 (31). Thus, mutation of these lysine residues delays sub-
sequent redistribution of STAT3 from the nucleus. Acetylation of 
K685 in the SH2 domain may represent the initial contact of p300 
with STAT3 (29–31, 38). K685 acetylation is reported to enhance 
DNA binding, transactivation activity, and nuclear localization of 
STAT3 (38, 39), although the conclusion that K685 is important 
for stable STAT3 dimer formation has been questioned based on 
structural considerations (52). Recently, evidence was provided 
that K685 acetylation is more important for gene expression by 
unphosphorylated STAT3 (U-STAT3), rather than in response to 
tyrosine-phosphorylated STAT3 (42). K685 acetylation has also 
been implicated in gene silencing by STAT3 via the targeting of 
the DNA methyl transferase, DNMT1 to certain promoters (40, 
41). Binding of STAT3 to DNMT1 is regulated by K685 acetyla-
tion of STAT3 by p300 (40).
Other lysine residues of STAT3 are likely targets of acetyla-
tion with functional consequences. For instance, repression of 
STAT3 transcriptional activity by the histone deacetylase Sin3a 
is reported to be dependent on K87 acetylation as the main 
regulator of STAT3–Sin3a interaction (32). In the liver, STAT3-
mediated inhibition of gluconeogenesis by gene suppression 
during the fed state was found to be regulated by a cluster of 
lysine residues (K679, K685, K707, and K709) in the C-terminus 
(37). Of particular note, Y705 phosphorylation and activation 
of STAT3 was found to be dependent upon acetylation of these 
residues and opposed during the fasting state by SIRT1. The basis 
for the positive role of multiple C-terminal acetylation sites on 
STAT3 activation and whether a similar scenario occurs in the 
heart awaits investigation.
Methylation and Mono-Ubiquitination
Posttranslational modification of various NH2-terminal lysine 
residues by methylation is a recently described mechanism that 
regulates STAT3’s transcriptional activity (28, 34, 35). Although 
reported thus far for cancer cells, lysine methylation is likely a 
basic transcriptional event important in cardiac cells as well. At 
least for K49 and K140, methylation occurs after STAT3 Y705 
phosphorylation and binding to certain promoters (28, 34, 53). 
Dimethylation of K49 and K140 by the histone modifying enzymes 
EZH2 and SET9, respectively, was shown to be important in regu-
lating expression of many IL-6-dependent genes in colon A4 can-
cer cells (28, 34). Dimethylation of K49 and K140 was associated 
TABLe 2 | Redox-sensitive cysteines of STAT3.
Residues (domain) Function
C259 (NTD) Responsible for cell lysis- and peroxide-induced 
dimers (57)
C328 (DBD), C542 (LD) Glutathionylation blocks JAK2-mediated Y705 
phosphorylation (56)
C418/C426/C488 (DBD), 
C765 (TAD)
Oxidation decreased DNA binding, SIE/c-fos 
promoter activity, and cell proliferation. Contribute 
(in various combinations) to peroxide-induced 
tetramer formation (59)
C418 (DBD), C712/C718 
(TAD), C765 (TAD)
Responsible for Prx2-induced dimers and 
tetramers (58)
DBD, DNA-binding domain; LD, linker domain; NTD, N terminus domain; TAD, 
transcription activation domain.
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with increased and decreased gene expression, respectively. 
Trimethylation of K180 by EZH2 was reported to enhance STAT3 
Y705 phosphorylation in glioblastoma cells, perhaps by block-
ing access of a tyrosine phosphatase (35). Interestingly, mono-
ubiquitination of another NH2-terminal lysine residue (K97) of 
STAT3 was implicated in recruitment of BRD4, a component of 
the activated positive transcriptional elongation factor (P-TEFb) 
complex, and induction of anti-apoptotic genes in HepG2 cells 
(33). Lastly, methylation of an arginine residue (R31) by PRMT2 
was reported to attenuate leptin-induced STAT3 activation in the 
hypothalamus (27). However, the role of arginine methylation as 
a regulatory feature of STAT3 is controversial and perhaps cell 
type-specific (54).
Redox-Sensitivity and Oxidation
Signal transducer and activator of transcription 3 has 14 highly 
conserved cysteine residues. Nine of these residues are reported to 
be redox-sensitive and to control STAT3’s transcriptional activity 
by inhibiting Y705 phosphorylation or DNA binding, inducing 
formation of higher order complexes (dimers and tetramers), or 
by interfering with the function of the TAD (Table 2) (55–61). In 
general, oxidative stress inhibits canonical STAT3 transcriptional 
activity. Although mitochondria are a major source of ROS, it 
is not known if the redox sensitivity of STAT3 contributes to 
its mitochondrial activity, either enhancing or inhibiting those 
actions.
Thiol targeting agents were reported to inhibit IL-6-induced 
STAT3 activation and increase its glutathionylation in HepG2 cells 
(55). These agents decreased nuclear accumulation of STAT3 and 
impaired expression of STAT3-target genes. S-glutathionylation 
of C328 and C542 within the DNA binding and linker domains, 
respectively, were shown to block JAK2-mediated phosphoryla-
tion of recombinant STAT3 Y705 likely due to steric or confor-
mational reasons (56). Peroxide was found to induce STAT3 
homodimer formation in HEK293 cells and a cysteine in the 
amino terminus was implicated (57). Cysteine residues within 
the DNA-binding domain and TAD appear to be especially 
crucial for STAT3 dimer and tetramer formation (58). Another 
study identified 3 redox-sensitive cysteines in the DNA-binding 
domain and one in the TAD (59). Oxidation of these cysteines by 
peroxide decreased STAT3 binding to an SIE in vitro and in vivo 
and IL-6-mediated reporter expression. Interestingly, evidence 
was reported that ROS may differentially affect STAT3 binding to 
DNA depending upon the nucleotide sequence of the promoter 
element, suggesting that the profile of genes activated by STAT3 
may be modulated by oxidative stress (59).
We found that STAT3 activation in cardiac myocytes is 
impaired by glutathione (GSH) depletion (60). Glutathione 
monoethyl ester, which is cleaved intracellularly to GSH, pre-
vented STAT3 inhibition, as did the reductant N-acetyl-cysteine. 
Notably, STAT1 activation was unaffected by GSH depletion. 
We also found that pre-treatment of human endothelial cells, 
neonatal rat cardiomyocytes, or adult mouse cardiac myocytes 
with thiolate-targeting electrophiles inhibited STAT3 activa-
tion and blocked induction of inflammatory genes (61). These 
compounds enhanced STAT3 glutathionylation with diamide 
treatment in adult cardiac myocytes and decreased the levels 
of STAT3 detected by Western analysis under non-reducing 
conditions. Thus, the redox-sensitive cysteines of STAT3 affect 
its cellular activation and availability in cardiac myocytes. 
Moreover, we found that STAT3 in the heart is affected by oxida-
tive stress in a disease state, as monomeric STAT3 levels were 
decreased under non-reducing conditions in the Gαq model of 
heart failure in a redox-sensitive manner (61). Whether STAT3’s 
transcriptional activity is similarly affected in human heart 
failure is not known.
Evidence was recently reported that the redox-sensitivity of 
STAT3 has physiological relevance as well in the context of redox 
signaling by cytokines involving hydrogen peroxide generation. 
Peroxiredoxin-2 was shown to associate with STAT3 in HEK293T 
cells in response to treatment with IL-6 or oncostatin M (58). This 
association resulted in the oxidation of multiple cysteine residues 
of STAT3 within the DNA-binding domain, linker domain, and 
TAD, subsequent higher order complex formation, and attenua-
tion of STAT3-mediated gene expression.
S-nitrosylation is a recently reported redox-related post-
translational modification that inhibits STAT3 activation. In 
microglial cells, endogenous NO from iNOS or treatment with 
s-nitrosoglutathione inhibited STAT3-induced gene expression 
and proliferation (36). STAT3 was observed to be s-nitrosylated 
on C259, which inhibited JAK2-mediated Y705 phosphorylation. 
Whether STAT3 is s-nitrosylated in the heart under conditions 
where iNOS is upregulated, such as the ischemic and failing 
myocardium, has not been reported.
CANONiCAL STAT3 SiGNALiNG
STAT3 and Cardioprotection: Main 
Signaling Pathways
Signal transducer and activator of transcription 3 signaling in 
cardiac myocytes in context is best illustrated by the induction 
of phosphorylation events downstream of LIF-induced dimeri-
zation of its membrane receptor LIFR with gp130 (Figure 3). 
Three major kinase cascades are activated with the central 
players being Akt, STAT3, and ERK1/2 that protect against 
oxidative or ischemic stress by acting on mitochondria or 
inducing gene transcription (62). LIFR and gp130 dimerization 
FiGURe 3 | LiF protects cardiac myocytes by both genomic and non-genomic means. Dimerization of gp130 and LIFR activates the associated JAK 
tyrosine kinases, which phosphorylate recruitment sites for STAT3 and STAT1 (YXXQ), and a scaffold protein SHP2 (YXXV) that is coupled to ERK1/2, ERK5, and 
phosphoinositide 3-kinase (PI3K)-Akt activation. STAT3 and the SHP2-based signaling pathways are linked to cellular protection and/or cell growth. JAK-mediated 
STAT3 phosphorylation on Y705 enhances its dimerization and DNA binding. Activated STAT3 induces expression of anti-apoptotic, anti-oxidative stress, and 
pro-angiogenic genes, and STAT3 S727 phosphorylation boosts gene transcription. In the nucleus, U-STAT3 may affect gene expression either as a transcription 
factor or by modulating chromatin structure. In parallel, STAT3 has protective actions on mitochondrial function. STAT3 optimizes mitochondrial respiration and limits 
ROS formation, thereby opposing mPTP opening and ensuring mitochondrial integrity. These non-genomic actions of STAT3 are enhanced by S727 
phosphorylation. ERK1/2 and Akt are components of the RISK pathway of cardiac protection that is evoked by pre- and postconditioning. ERK1/2 has protective 
effects on mitochondria via phosphorylation and inhibition of GSK3-α/β, which prevents mPTP opening. PI3K-Akt signaling also inhibits opening of mPTP via 
phosphorylation of GSK3-α/β or mitochondrial hexokinase II (HKII). See text for additional details. Adapted with permission from Zouein et al. (62).
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activates the associated JAKs, which phosphorylate recruitment 
sites for STAT3 (YXXQ) and a scaffold protein SHP2 (YXXV) 
linked to activation of ERK1/2, ERK5, and Akt (1, 62). These 
signaling pathways are linked to cellular protection and/or cell 
growth. STAT3 is activated by phosphorylation on Y705 by the 
JAKS, which leads to its dimerization and translocation to the 
nucleus. STAT3 is also phosphorylated by ERK1/2 on S727, 
which enhances its transcriptional activity (1, 3). Activated 
STAT3 induces expression of anti-apoptotic, anti-oxidative 
stress, and pro-angiogenic genes. STAT3 also optimizes mito-
chondrial respiration and limits ROS formation from complex 
I with ischemia, and these mitochondrial actions of STAT3 are 
enhanced by S727 phosphorylation (5). ERK1/2 couples to cell 
growth via an impact on transcription factors and intracellular 
increases in Ca2+, which activates calmodulin and the serine/
threonine phosphatase calcineurin (not shown) (62). This in 
turn activates gene transcription (via NFAT) or de-represses 
cardiac gene expression via Ca2+/calmodulin-dependent pro-
tein kinases II (CamKII). ERK1/2 also has protective effects on 
mitochondria via phosphorylation and inhibition of GSK3-β, 
which prevents opening of mPTP (62). The phosphoinositide 
3-kinase-Akt signaling network also inhibits opening of mPTP 
via phosphorylation of GSK3-β or mitochondrial hexokinase 
II (HKII) (62). Akt may also inhibit apoptosis and autophagy 
via phosphorylation of mTOR complex 1 (mTORC1), Bad, and 
Bax (not shown). Akt activation is linked to protective gene 
expression too.
STAT3 in Acute and Chronic  
Cardiac Stress
Ischemia
Signal transducer and activator of transcription 3 has been 
implicated in protecting the heart from acute myocardial injury 
due to ischemia and ischemia–reperfusion (1, 3). STAT3 has 
also been implicated in the protection of the heart produced by 
various forms (ischemic, pharmacological, direct and remote) of 
pre- and postconditioning (3). For preconditioning, STAT3 has 
been implicated in both the early short-lived phase that does 
not involve gene expression and the delayed longer-lived phase 
that involves gene expression, known as the second window of 
protection (1). Many of these studies relied on JAK2 or STAT3 
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inhibitors, and thus the evidence in those cases implicating 
STAT3 is circumstantial.
Definitive evidence that STAT3 protects the heart from 
acute ischemic injury has been obtained from cardiac myocyte-
targeted STAT3 knockout (KO) mice. Smith et al. reported that 
depletion of cardiac STAT3 did not affect infarct size; however, 
STAT3 was found to be crucial for preconditioning protocols 
(63). Hilfiker-Kleiner et  al. also tested the role of STAT3 in 
ischemia–reperfusion and infarction using cardiac myocyte 
STAT3 KO mice (64). They observed greater infarct size and 
apoptosis 24  h after reperfusion in KO hearts with impaired 
fractional shortening after 7 days. Increased mRNA levels of the 
pro-apoptotic and pro-autophagy protein BNIP3 were observed 
24  h after reperfusion, while mRNA levels of the prosurvival 
gene HSP70 were decreased. No changes were seen in VEGF 
expression, which is pro-angiogenic and previously linked to 
STAT3 overexpression or activation in the heart (65–67), as 
was the mitochondrial anti-oxidant protein SOD2 (68). STAT3 
KO mice also exhibited a marked increase in mortality with 
myocardial infarction (MI). Using an inducible cardiac myocyte 
targeted STAT3 KO model, Bolli et al. reported that deletion of 
STAT3 eliminated the upregulation of antiapoptotic (e.g., Mcl-1, 
Bcl-xL, c-FLIPL, and c-FLIPS) and cardioprotective (COX-2 and 
HO-1) proteins normally induced in delayed preconditioning 
(69). Using a similar model, Enomoto et  al. recently reported 
that STAT3 expression in cardiac myocytes contributes to 
remodeling during the subacute phase of MI (70). Deletion 
of STAT3 during days 11–24 after MI, resulted in worsened 
cardiac function and increased mortality. STAT3 ablation 
exacerbated cardiac fibrosis during the subacute phase of MI, 
along with an increased expression of fibrosis-related genes, 
presumably due to increased death of cardiac myocytes. Cardiac 
hypertrophy was enhanced by STAT3 ablation after MI and 
consequently capillary density was reduced in the border zone. 
Again, no change in VEGF expression was detected. Although 
the proper controls were performed, interpretation of these 
results may be complicated by the likely tamoxifen-induced 
cardiomyopathy that occurs in hearts expressing MerCreMer 
(71). Nonetheless, the study does support the conclusion that 
STAT3 has protective effects in the heart during the subacute 
phase post-MI. This conclusion is also supported by the results 
of a study that examined the impact of cardiac-specific deletion 
of SOCS3 on left ventricular remodeling after MI (72). SOCS3 
is the intrinsic negative feedback inhibitor of STAT3 signaling. 
In SOCS3 KO mice, infarct size was markedly reduced 14 days 
after MI, as were myocardial apoptosis and fibrosis. Multiple 
protective signaling pathways were enhanced by SOCS3 dele-
tion, including STAT3, as well as expression of antioxidants 
HO-1 and SOD2. Survival and cardiac function were improved. 
A similar finding of reduced myocardial injury after 24 h was 
observed with ischemia–reperfusion in SOCS3 KO mice and 
this was associated with increased expression of anti-apoptotic 
Bcl-2 family member myeloid cell leukemia-1 (Mcl-1), a gene 
target of STAT3 (73). In light of these findings, it is surprising 
that continuous activation of STAT3 in cardiac myocytes via a 
mutant gp130 receptor was associated with a worse outcome 
in subacute MI due in part to increased inflammation (74). 
The impact of concurrent signaling events in the later study on 
STAT3 signaling offers a possible explanation (75).
SAFE Signaling
Two major signaling pathways have been identified as contribut-
ing to the infarct-sparing effect of pre- or postconditioning. The 
Reperfusion Injury Salvage Kinases (RISK) pathway was identi-
fied first and entails activation with reperfusion of pro-survival 
kinases extracellular regulated kinase 1/2 (ERK1/2) and Akt 
that converge on mitochondria to decrease mPTP opening (76). 
The Survivor Activating Factor Enhancement (SAFE) pathway 
is a “RISK-free” mechanism of cardiac protection that was 
originally linked to the activation of TNF during reperfusion 
and the induction of JAK–STAT3 signaling by TNF receptor-1 
(TNFR-1) (76). The relative contribution and importance of the 
RISK and SAFE pathways to myocardial protection can vary 
with the experimental ischemic protocol (pre- vs. postcondi-
tioning, direct vs. remote), as well as species. Some studies have 
identified a role for SAFE signaling in the initiation of the RISK 
pathway in protecting the heart by pre- and post-conditioning, 
although the basis for this is not defined (7, 77, 78). Given their 
clinical relevance, it is of note that SAFE activation is critical for 
protecting the heart by both remote pre- and postconditioning 
in larger mammalian species, such as pigs and humans, while 
RISK signaling is dispensable (76, 79). Interestingly, in humans 
STAT5 and not STAT3 is involved in remote ischemic precon-
ditioning (80).
Besides, TNF, other agonists have been implicated in SAFE 
signaling, including sphingosine-1-phosphate, insulin, and 
IL-10 (7, 81, 82), and possibly SDF-1α (83). SAFE signaling pro-
tects the heart by both transcriptional and non-transcriptional 
means. Concerning the latter, the downstream targets are not 
well characterized, but may include direct STAT3-mediated 
suppression of NF-κB activity (84), phosphorylation of pro-
apoptotic Bad protein (85), or inhibition of mPTP opening 
(86, 87). Ischemia or ischemia–reperfusion is reported to 
induce the translocation of STAT3 to mitochondria in heart by 
undefined means (88, 89), supporting the conclusion that the 
direct mitochondrial actions of STAT3 contribute to the protec-
tion afforded by SAFE signaling; although, this has not been 
definitely demonstrated.
Pregnancy
The heart is more vulnerable to ischemia–reperfusion injury in 
late pregnancy, and this is associated with impaired activation 
of protective signaling, including STAT3 (90). In addition, mice 
with cardiac myocyte-targeted STAT3 deletion develop a form 
of peripartum cardiomyopathy (PPCM) (91), a life-threatening 
condition that affects previously health women in the last month 
of pregnancy or the first months after giving birth. In hearts of 
STAT3 KO mice, pregnancy was found to be associated with 
increased oxidative stress due to blunted SOD2 expression (92, 
93). This in turn leads to increased cathepsin D expression and 
activity, which generates a cleaved anti-angiogenic and pro-
apoptotic 16  kDa form of the nursing hormone prolactin that 
impairs the vasculature thereby compromising cardiac myocyte 
metabolism. Serum levels of activated cathepsin D and 16 kDa 
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prolactin are elevated in PPCM patients as well (92). The relevance 
of these findings to the etiology of human PPCM is uncertain, 
however. While titin gene mutations were found to be common 
in families with both peripartum and dilated cardiomyopathies, 
no STAT3 mutations were identified in the PPCM cases that were 
examined (93). On the other hand, left ventricular STAT3 protein 
levels are decreased in patients with end-stage heart failure due 
to PPCM (91).
Aging
Two lines of evidence support the importance of STAT3 in the 
heart with aging. First, cardiac STAT3 levels are reduced with age 
in various cell types and tissues, including the rodent heart (8, 
9), but whether cardiac STAT3 levels are reduced with advanced 
age in humans is not reported. Second, mice with postnatal car-
diac myocyte-targeted STAT3 KO encompassing exons for the 
DNA-binding domain develop heart failure with age (64). This is 
attributed in part to increase miR-199a-5p levels that were asso-
ciated with increased asymmetric dimethylarginine (ADMA) 
synthesis, which in turn was linked to cardiac endothelial 
dysfunction, capillary loss, and potentially myocardial ischemia 
(94). Evidence suggests that STAT3 functions as a direct repressor 
of the promoter for miR-199a-5p and with total STAT3 KO in 
the adult mouse heart there was found to be a massive increase 
in levels of miR-199a-5p, which was linked to disturbance in 
the ubiquitin-proteasome system (UPS) due to suppression of 
ubiquitin conjugating enzymes (Ube) Ube2i and Ube2g1. Besides 
increased ADMA synthesis due to increased PRMT-1 levels, sup-
pression of Ube2i and Ube2g1 in cardiac myocytes in vivo and 
in vitro was associated with downregulation of a- and β-myosin 
heavy chain (MHC) and derangement of sarcomeres. However, 
adult STAT3 KO hearts display normal levels of α- and β-MHC 
and SERCA2a (64), suggesting a potentially greater impact of 
increased ADMA levels to the pathology of the STAT3 KO hearts 
in vivo than sarcomere disruption.
Summary
Signal transducer and activator of transcription 3 is protective 
to the heart under acute ischemic conditions via canonical 
means involving transcription of anti-oxidative, anti-apoptotic 
and pro-angiogenic genes. In addition, STAT3 has poorly 
understood actions in protecting the heart from ischemia 
that may involve non-canonical actions in mitochondria (see 
below). Evidence also indicates that STAT3 is protective to the 
heart under chronic stress conditions, such as hypertension, 
pregnancy, and advanced age. The protective role of STAT3 in 
hypertension-induced cardiac hypertrophy has not been well 
studied, but in addition to involving transcriptional events likely 
involves non-canonical interactions with NF-κB (see below). In 
pregnancy and with aging, STAT3 in cardiac myocytes has been 
shown to be a critical determinant of endothelial function and 
health, although by different mechanisms: induction of protec-
tive anti-oxidant genes is important in pregnancy, whereas loss 
of STAT3-mediated repression of miR-199a expression may 
contribute to endothelial dysfunction in the heart with aging. 
The mechanism by which STAT3 represses gene expression in 
the heart is not known, as is the question of whether gene repres-
sion and induction by STAT3 involve distinct posttranslational 
regulatory mechanisms.
NON-CANONiCAL STAT3 SiGNALiNG
U-STAT3 and Chromatin Remodeling
There is evidence that STAT3 in the heart regulates different 
sets of genes by two basic means: canonical (phosphorylated on 
Y705 and S727) and unphosphorylated STAT3 (U-STAT3) (1). 
In canonical signaling, Y705 phosphorylation favors formation 
of STAT3 parallel dimers that tightly bind to GAS elements 
in promoters and induce gene expression via assembly of an 
enhanceosome. Canonical signaling is associated with both 
inflammation (74) [although STAT3 has anti-inflammatory 
actions via non-canonical means (95)] and the protection from 
acute ischemic stress by upregulation of cardioprotective and 
anti-apoptotic proteins, including COX-2, HO-1, Mcl-1, Bcl-xL, 
c-FLIPL, and c-FLIPS (69, 72, 73). Phosphorylation of STAT3 on 
S727 is thought to enhance canonical transcription by increasing 
recruitment of the histone acetyltransferase p300 (1, 44). S727 
phosphorylation has also been implicated in the recruitment 
of tyrosine phosphatases, thereby attenuating canonical STAT3 
signaling (49, 50).
U-STAT3 (aka latent STAT3) arises from canonical STAT3 
signaling-induced STAT3 expression (96). U-STAT3 levels (with 
no Y705 or S727 phosphorylation) were shown to increase in 
nuclei of mouse hearts overexpressing the AT1 receptor and in 
neonatal rat ventricular myocytes treated with angiotensin II 
(97). U-STAT3 levels correlated with the degree of hypertrophy 
and U-STAT3 was postulated to induce a subset of inflammatory 
and pro-hypertrophic genes in the heart (97), although definitive 
evidence for this was not provided. It has been proposed that 
U-STAT3 serves as a means to prolong the inflammatory response 
initiated by canonical STAT3 signaling (96).
Some of the genes activated by U-STAT3 respond to its com-
plex with unphosphorylated p65 subunit of NF-κB, and binding is 
not to GAS elements, but to a specific type of κB element in DNA 
that supports both binding of p65 homodimers and cooperatively 
with U-STAT3 (98). STAT3 S727 phosphorylation is not required, 
at least for the interaction of U-STAT3 with the p65 subunit (98). 
The role of S727 phosphorylation in U-STAT3-induced gene 
expression has not been systematically evaluated, although evi-
dence reported to date indicates that S727 phosphorylation is not 
important (97, 98). In this regard, U-STAT3 is generally used to 
refer to non-tyrosine phosphorylated STAT3 without specifying 
the phosphorylation status of S727.
Nothing is known about how U-STAT3 activates the remain-
ing target genes that do not require NF-κB (96). Presumably, these 
genes are activated by binding of U-STAT3 to a GAS or GAS-like 
element. Recently, acetylation of STAT3 on K685 was found to be 
required for the expression of most U-STAT3-dependent genes, 
with K685 acetylation having only a minor role in the expression 
of genes by tyrosine phosphorylated STAT3 (42). K685 may be 
important for the recruitment of p300 and/or K685 acetylation 
may facilitate stable STAT3 dimer formation in the absence of 
Y705 phosphorylation.
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The possibility that U-STAT3, which tends to form anti-
parallel dimers, also acts as a dominant negative mutant protein 
cannot be discounted (97). Moreover, the pathophysiological 
relevance of the AT1 overexpressing heart is uncertain, as adult 
cardiac myocytes express low levels of AT1 receptors and the 
hypertrophic actions of angiotensin II on the adult heart are 
attributable to increased blood pressure and not a direct effect on 
cardiac myocytes (99). Whether U-STAT3 accumulates in heart 
nuclei in other models of cardiac hypertrophy will need to be 
assessed.
Unphosphorylated STAT3 can bind GAS elements as a 
monomer or dimer, but binding is much weaker than seen with 
STAT3 phosphorylated on pY705 (100). Remarkably, U-STAT3 
(non-tyrosine phosphorylated STAT3) binds more strongly 
to AT-rich DNA sequence sites and sequences common in S/
MAR DNA elements that are implicated in chromatin organiza-
tion (100). U-STAT3 also recognizes specific DNA structures, 
such as DNA nodes and four-way junctions that are involved 
in nucleosomal structure and assembly. These observations 
suggest that non-tyrosine phosphorylated STAT3 influences 
chromatin organization. Consistent with this possibility is the 
observation that deletion of the Drosophila STAT homolog 
Stat92E disrupts heterochromatin integrity and allows for 
transcriptional activation of genes that are not direct targets 
of Stat92E (101). Additionally, evidence indicates that Stat92E 
interacts with heterochromatin protein 1 (HP1) to regulate 
histone 1 (HI) and histone 3 (H3) function (102, 103). This 
epigenetic role of Stat92E is disrupted by its tyrosine phospho-
rylation and subsequent translocation of Stat92E to target genes 
(102). Evidence was recently reported that STAT5A functions 
similarly in several human cancer cells to maintain nucleosomal 
structure (104). Notably, STAT3, like Stat92E and STAT5A, 
possesses a conserved pentapeptide motif (PxVxI) for the 
binding of HP1. The question of whether STAT3 is important 
for heterochromatin stability in cardiac myocytes will need to 
be addressed, especially under stress conditions such as cardiac 
hypertrophy or heart failure.
Consistent with an extra-transcriptional role for STAT3 in the 
nucleus is the observation that the nuclei of various cell lines and 
primary cells contain substantial levels of U-STAT3 under non-
stimulated conditions, i.e., ~40% of total cellular STAT3 (105, 
106). Nuclear import of both U-STAT3 and tyrosine phosphoryl-
ated STAT3 is an energy requiring process involving the nuclear 
shuttle proteins, importin-α3 (-α6 in testes) and -β1 (106–109). 
Tyrosine phosphorylated STAT3 may also bind importin-α5 and 
-α7 (110, 111). A region (amino acids 150–162) within the coiled-
coil region of STAT3 is critical for its recognition by importin-α3 
and constitutive STAT3 nucleocytoplasmic trafficking (106). For 
tyrosine phosphorylated STAT3, but not U-STAT3, R214/215 in 
the α-helix 2 region of the coiled-coil domain is also required 
for nuclear import (111, 112). For either tyrosine phosphoryl-
ated or unphosphorylated STAT3, dimer formation (parallel and 
antiparallel, respectively) is not required for nuclear uptake (106, 
113). Tyrosine phosphorylation does not affect STAT3 nuclear 
import; however, nuclear accumulation of STAT3 is determined 
by DNA binding, which is enhanced by tyrosine phosphorylation. 
Consequently, STAT3 S727 phosphorylation, which enhances 
recruitment of a tyrosine phosphatase, attenuates STAT3 nuclear 
accumulation (50).
Nuclear export of activated STAT3 is dependent upon its asso-
ciation with the class I histone deacetylase HDAC1, which in turn 
requires NH2-terminal acetylation of STAT3 (31). Brasier’s group 
has proposed that the binding of HDAC1 to STAT3 exposures 
one or more of the three nuclear export sequences (NESs) of 
STAT3 to the exportin CRM1. The nuclear export of stimulated 
and non-stimulated (latent) STAT3 is in part mediated by CRM1 
(108, 113, 114). Two of the three NESs of STAT3 may be involved 
in constitutive export, while the third may be important for 
poststimulation export (115). In addition, there is some sugges-
tion that U-STAT3 may shuttle between cytoplasm and nucleus 
independent of NLSs or NESs (113, 116). Neither nuclear import 
nor export of STAT3 has been well studied in cardiac myocytes.
interactions of STAT3 with NF-κB
Signal transducer and activator of transcription 3 and NF-kB sign-
aling pathways interact at multiple levels in the cytosol, nucleus, 
and at various promoters. Activated (tyrosine phosphorylated 
and acetylated) STAT3 has been shown to interact with canoni-
cal NF-κB signaling, as well as with the non-canonical NF-kB 
pathway (1, 98, 108). In many cases, STAT3 serves to promote 
the survival and pro-growth actions of NF-kB activation. For 
instance, (1) in several human cancer cell lines phosphorylated 
Y705 and acetylated K685 STAT3 was implicated in the process-
ing of NF-κB p100, which has pro-apoptotic and anti-oncogenic 
function, to the anti-apoptotic and oncogenic protein p52 (117); 
and (2) the enhanced nuclear NF-κB p65 levels that are frequently 
observed in cancer cells was attributed to p65 acetylation brought 
about by the binding of p65 to activated STAT3 in association 
with p300 (118). Evidence was reported that the opposite scenario 
occurs in the heart. IL-10, via activation of STAT3 signaling, was 
found to inhibit NF-κB-mediated hypertrophic and inflamma-
tory gene expression by blocking NF-κB p65 activation in the 
cytosol (95). Exactly how this occurs, and whether inhibition 
is direct or indirect was not resolved. A conundrum for cardiac 
STAT3 signaling is why some cytokines that activate this protein, 
such as IL-6 are pro-inflammatory, while others such as IL-10, are 
anti-inflammatory (119). The temporal pattern of STAT3 activa-
tion and the consequent impact that would have on its interaction 
with NF-κB signaling may provide an explanation (75).
STAT3 and Mitochondria
In 2009, the seminal observation was reported that STAT3 is 
present in the mitochondria of mouse hearts and loss of STAT3 
is associated with mitochondrial dysfunction (46). Numerous 
reports subsequently established that STAT3 is found in mito-
chondria of various cell types and tissues and mitochondrial 
STAT3 has functional consequences. Approximately 30% of these 
reports involve cardiac myocytes or hearts and an equal number 
are cancer-related. In many cases, loss of STAT3 was accompa-
nied by reduced activities of respiratory complexes I and II (4, 5). 
In mouse Stat3−/− pro-B cells, deficient activities of complexes I 
and II were restored by expressing mutant STAT3 proteins with 
a phosphorylation refractory Y705F residue and either an intact 
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S727 or a phosphomimetic S727 residue (46). A STAT3 protein 
unable to bind DNA or form dimers restored complex activities, 
while a STAT3 with a phosphorylation refractory S727A residue 
was ineffective. Thus, S727 phosphorylation is an important 
determinant of the mitochondrial actions of STAT3. Consistent 
with this conclusion are reports that S727 phosphorylation of 
mitochondrial STAT3 is required for the oncogenic growth 
of cancer cells (47, 48, 120–122). Which kinase or kinases are 
responsible for mitochondrial STAT3 S727 phosphorylation in 
cardiac myocytes is undefined, although the ERK pathway was 
found to be necessary for S727 phosphorylation of mitochondrial 
STAT3 and Ras-mediated transformation in human cancer cells 
(47). Whether other residues of STAT3 are phosphorylated and 
important for its mitochondrial actions is unknown, or whether 
STAT3 undergoes other posttranslational modifications in mito-
chondria such as acetylation.
In some cases, loss of STAT3 was associated with increased 
mitochondrial ROS production by undefined means (1, 4), but 
it is not reported whether loss of STAT3 enhances mitochondrial 
ROS in the heart. A few studies reported that loss of STAT3 
impairs mitochondrial membrane potential, but this has not been 
systematically investigated (1, 4). Mitochondria from hearts of 
mice with postnatal cardiac myocyte-targeted STAT3 KO have 
enhanced calcium-sensitivity of mPTP opening (87). Although 
STAT3 was reported to co-IP with pore component cyclophilin 
D from rat heart mitochondria (87), it is unlikely based on 
stoichiometry that STAT3 opposes mPTP opening strictly by 
this mechanism (123). Decreased mitochondrial membrane 
potential due to reduced complex I activity may partially explain 
increased calcium-sensitivity of mPTP opening. Recently, MLS-
STAT3E mice with cardiac myocyte-specific overexpression 
of mitochondria-targeted STAT3 with a mutation in the DNA-
binding domain were generated (88). Inexplicably, MLS-STAT3E 
expressing mitochondria have a modest decrease in complex I 
activity; however, these mitochondria have a normal membrane 
potential and are protected against ischemic damage to complex 
I and release of cytochrome c into the cytosol. Compared to wild 
type mitochondria, ischemia does not enhance ROS production 
by MLS–STAT3E mitochondria (88).
Damage to complex I occurs during ischemia and leads to 
enhanced ROS formation during reperfusion that may further 
damage complex I (124, 125). Activity of complex I and/or other 
complexes is also reported to be reduced in various animal mod-
els of cardiac hypertrophy and heart failure, as well as human 
cardiomyopathies and heart failure (126–129). In these cases, 
mitochondrial dysfunction and enhanced ROS formation occur 
as well, but the importance of mitochondrial STAT3 to protecting 
mitochondrial respiration and integrity in chronic stress situa-
tions of the heart is not well studied.
The functional consequences of impaired complex I activity in 
cardiac hypertrophy and heart failure are not established; however, 
defects in complex I likely have significance beyond impaired ATP 
synthesis. As mentioned, complex I contributes to mitochondrial 
membrane potential and regulates mPTP opening (130–132). As 
NADH dehydrogenase, complex I is important in NAD+/NADH 
redox balance (131). Recently, deficiency of complex I activity 
due to KO of the Ndufs4 gene, which encodes a critical subunit 
of complex I, was reported to accelerate the progression to heart 
failure in the transverse aortic constriction (TAC) mouse model 
(133). Complex I deficiency correlated with an increase in NADH 
levels, which was associated with an increase in mitochondrial 
protein acetylation that was postulated to result from an inhibi-
tory action of NADH and/or loss of NAD+ on SIRT3 activity. 
Pathological cardiac hypertrophy is associated with reduced 
intracellular NAD+ levels (134), and reduced SIRT3 activity could 
feed forward to further impair and cause damage to complex I. 
SIRT3 is positively linked not only to electron transport chain 
(ETC) and tricarboxylic acid (TCA) cycle activities (135, 136), 
but mitochondrial anti-oxidant defenses by increasing SOD2 
activity (137) and maintaining mitochondrial GSH levels (138). 
We recently reported that hearts of SIRT3-deficient mice produce 
more ROS and show greater dysfunction when mitochondria are 
stressed as with a high fat diet (139). Others have shown that 
SIRT3 KO mice go into heart failure more rapidly with TAC (140) 
and are more susceptible to ischemia–reperfusion injury (141). In 
addition, in post-infarction heart failure in diabetic rats, reduced 
SIRT3 expression was associated with increased mPTP open-
ing and acetylation of its activator, cyclophilin D (142). Thus, 
by maintaining complex I activity, STAT3 may preserve SIRT3 
activity and mitochondrial integrity.
Complex I is also essential for respirasome (i.e., supercomplex) 
assembly in mitochondria (143). Decreased respirasomes lead-
ing to greater ROS has been proposed to drive the progression 
to heart failure (144, 145). Moreover, unincorporated complex 
I generates superoxide responsible for damage to mitochondrial 
DNA and the lipids and proteins of the inner membrane, includ-
ing components of the ETC, that occurs in heart failure (145). 
Recently, increased levels of the matrix arm of complex I that are 
not incorporated into a fully assembled complex were linked to 
increased ROS production and aging in the mouse (146).
The mechanism by which STAT3 protects complex I and 
modulates mitochondrial metabolism is not known (Figure 4). 
The reported greater abundance of complex I/II to STAT3 in 
cardiac myocytes suggests that STAT3 affects mitochondrial 
function indirectly for example by serving as a scaffold protein 
that facilitates the posttranslational modification of some other 
protein (1). However, STAT3 was detected within complex I of 
liver mitochondria by Western immunoblotting suggesting that 
STAT3 may be further processed within mitochondria (46). 
STAT3 is an established binding partner of GRIM19 (complex I 
subunit B16.6 or NDUFA13), a critical supernumerary protein of 
complex I (45, 51). Association of GRIM19 with STAT3 occurs 
through the C-terminus of STAT3 and is positively affected by 
S727 phosphorylation. Uptake of STAT3 by isolated rat heart 
mitochondria is mediated by GRIM19, enhanced by STAT3 
S727 phosphorylation, and requires mitochondrial membrane 
potential and energy (45).
GRIM19 is the only hydrophobic protein in the hydrophilic 
portion of the matrix arm of complex I (148, 149). Single-particle 
electron cryomicroscopy of bovine heart complex I places 
GRIM19 in the heel region of complex I, extending from the 
inner mitochondrial space into the matrix arm as far as NDUFS8 
FiGURe 4 | Postulated role of STAT3 in mitochondria. STAT3 may function directly or indirectly (e.g., by serving as a scaffolding protein for the posttranslational 
modification of a subunit protein) as a rheostat to ensure complex I function and prevent excessive ROS production, which would feedback and cause damage to 
complex I. STAT3 may also interact with cyclophilin D and thereby prevent opening of the mitochondrial permeability transition pore (mPTP) and subsequent 
disruption of mitochondrial integrity and function through the influx of solutes and water. Additional sites within the ETC where STAT3 may have positive functional 
actions, include complex II and ATP synthase (complex V). A possible engagement of STAT3 with complex V is postulated based on the observation that complex V 
activity is markedly reduced with STAT3 loss in Ras-transformed cells (120) and recent evidence identifying mPTP as the c-subunit of the F1FO ATP synthase (147).
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and spanning the inner mitochondrial membrane alongside ND1 
(150). GRIM19 is reported to interact with NDUFA9 located 
in the transition region of complex I that anchors the matrix 
arm to the membrane and which undergoes a conformational 
change with hypoxia (151, 152). GRIM19 also is reported to 
interact with NDUFS3 and NDUFS4, which would place it close 
to the ubiquinone-reaction chamber formed by NDUFS2 and 
NDUFS7 (151, 153–156), a source of ROS during ischemia (157, 
158). GRIM19 is important for both assembly of complex I and 
maintaining mitochondrial membrane potential (151, 159, 160). 
These functions occur independently of each other and are medi-
ated by distinct regions. The region important for maintaining 
membrane potential (70–100) spans a predicted α-helix (74–98) 
and is adjacent to the conserved site of GRIM19 phosphorylation 
[T113] (151, 159, 161). Deletion of residues 70–80, 90–100, or the 
entire C-terminus of GRIM19 reduces mitochondria transmem-
brane potential and enhances sensitivity of mPTP opening (159). 
The importance of GRIM19 T113 phosphorylation is not known, 
but loss of S250 phosphorylation in another supernumerary 
subunit of complex I (NDUFA10) was recently shown to result in 
reduced ubiquinone reduction by complex I and mitochondrial 
depolarization (162). NDUFA10 is also located close to ND1 and 
ND3, which form a tunnel for ubiquinone access to the reaction 
chamber (154–156, 162). The role of STAT3 in GRIM19 phospho-
rylation is not known.
Based on the interaction of STAT3 with GRIM19, STAT3’s 
importance to complex I activity, and the impact of both 
GRIM19 and mitochondria-targeted STAT3 in preserving com-
plex I integrity and membrane potential, it may be postulated 
that STAT3, via interaction with GRIM19, contributes to sta-
bilizing the junction region between the matrix and membrane 
arms of complex I (48). This would ensure effective coupling of 
the matrix arm, involved in electron transfer from NADH to 
ubiquinone, to the membrane arm involved in proton pump-
ing. Effective coupling may also limit electron leakage and ROS 
production from complex I, as the N2/ubiquinone binding site 
is a potential source of ROS (157). In fact, evidence derived 
from MLS-STAT3E mitochondria places the contribution of 
STAT3 to complex I activity downstream of the FMN moiety 
and in the vicinity of the N2/ubiquinone site, as there is a lack of 
ischemia-induced ROS in MLS–STAT3E mitochondria whereas 
NADH-ferricyanide reductase activity is unaffected (88). 
Consistent with this scenario are recent observations that breast 
cancer cells expressing mitochondria-targeted (MLS) STAT3 
with a S727A mutation exhibit slower tumor growth, decreased 
complex I activity, and increased ROS accumulation under 
hypoxia compared with cells expressing MLS–STAT3 (48). On 
the other hand, cells expressing phosphoserine mimetic MLS-
STAT3 S727D show enhanced growth and complex I activity, 
and decreased ROS production.
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Mammalian complex I exists in two states, active (A) and 
de-active (D) (163–165). The state of complex I is determined by 
availability of substrates, divalent cations, and temperature. The 
A-form predominates over the D-form when sufficient substrates 
are available (NADH and ubiquinone) and at physiological tem-
peratures. The A-form spontaneously converts into the D-form 
when substrate concentrations are reduced. Under normoxic 
conditions, 5–15% of complex I is in the D-form. Ischemia causes 
low substrate availability and favors the D-form, but the D-form 
reactivates into the A-form when substrates become available 
during reperfusion. The molecular mechanism behind the A/D 
transition is not known; however, involvement of three complex I 
subunits in the region of the ubiquinone binding site is proposed: 
39 kDa accessory subunit NDUFA9 and mitochondrial encoded 
subunits, ND3 and ND1 that are involved in proton pumping (152, 
166). The region around the matrix loop of ND3 is involved in 
conformational changes that occur during the A/D transition and 
selective fluorescence labeling and proteomic analysis on bovine 
heart mitochondria revealed that C39 of ND3 is exposed only 
in the D-form (152). Exposed C39 can be s-nitrosylated under 
hypoxic conditions, arresting complex I in the D-form (152, 164, 
167). A recent study showed that s-nitrosylation of C39 of ND3 
can be exploited to protect the heart from ischemia–reperfusion 
injury (168). Treatment of mice with a mitochondria-targeted 
nitrosylatng agent (MitoSNO) at reperfusion reduced ROS pro-
duction, oxidative damage, and tissue necrosis. The explanation 
offered for this protection is that prolonging the time complex 
I spends in the D-form dampens the burst of respiration that 
occurs during reperfusion, thus limiting overall ROS forma-
tion from downstream sites in the ETC (164, 168). Notably, the 
D-form of complex I itself produces more ROS than the A-form 
and is more susceptible to ischemic damage (165, 169). Given 
the ability of STAT3 to reduce ROS formation from complex I, 
we assessed whether the A/D transition was deficient in complex 
I of MLS–STAT3E mitochondria; however, the A/D transition 
was clearly not affected by overexpressing mitochondrial STAT3 
based upon functional measurements (Drs. Chen and Lesnefsky, 
unpublished observation).
The protective actions of STAT3 on respiration may involve 
other scenarios. Recently, mitochondrial-targeted STAT3 was 
shown to be required for the protective actions of prohibitin 
1 against TNF-induced mitochondrial stress and apoptosis of 
cultured intestinal epithelial cells (170). Prohibitin 1, an abundant 
protein of the mitochondrial inner membrane, helps maintain 
mitochondrial structure and function and is required for optimal 
activity of complexes I and IV. STAT3 was found to interact with 
prohibitin 1 and this interaction was dependent on S727 phospho-
rylation. In activated CD4+ T cells, mitochondrial STAT3 (in this 
case, only pY705 STAT3 was assessed, but likely pS727 was involved 
as well) was implicated in the formation of ETC supercomplexes 
downstream of IL-6 (171). Formation of the supercomplexes 
resulted in mitochondrial hyperpolarization that was uncoupled 
from ATP production by oxidative phosphorylation and mitigated 
ROS production. Mitochondrial hyperpolarization allowed for 
increased mitochondrial calcium uptake and consequently higher 
cytosolic calcium that drove the expression of certain cytokines 
linked to inflammation during late activation of these T cells.
Summary
The non-canonical actions of STAT3 involve gene induction by 
U-STAT3 that may sustain a hypertrophic and inflammatory 
gene program in the heart in response to hypertension; however, 
definitive evidence for that conclusion is lacking. In addition, 
U-STAT3 or non-tyrosine phosphorylated STAT3 may have a 
role in genomic stability in the heart particularly under stress 
conditions. Although STAT3 is also known to interact with 
NF-κB in non-cardiac cells by various means, the importance 
if this interaction to the heart is not well studied. Evidence that 
STAT3 attenuates the contribution of NF-κB to hypertrophy and 
inflammation in the heart due to pressure overload would sug-
gest that STAT3 activation could be exploited to protect the heart 
from hypertension-induced cardiac remodeling. Finally, STAT3 
has been implicated in regulating mitochondrial respiration and 
limiting ROS production from the ETC. However, the molecular 
basis for the direct protective actions of STAT3 on mitochondria 
is not established. The finding that hearts of mice overexpressing 
a mitochondrial targeted STAT3 are protected from ischemia–
reperfusion injury provides some hope that the mitochondrial 
actions of STAT3 could be exploited therapeutically.
CONCLUSiON AND FUTURe DiReCTiONS
Much has been revealed about the role of STAT3 in the heart 
under acute stress such as ischemia and ischemia–reperfusion, 
and chronic stress such as pregnancy and aging. There is a 
general consensus that STAT3, in response to external stimuli, 
acts as a multifaceted protective protein by maintaining cel-
lular homeostasis and antioxidant defenses. The activation and 
recruitment of STAT3 to induce both genomic and non-genomic 
activities is highly regulated by multiple posttranslational modi-
fications, such as phosphorylation, acetylation, methylation, 
mono-ubiquitination, and oxidation. The co-ordination and 
integration of these posttranslational modifications in the heart 
in response to external stimuli is not well defined. Interestingly, 
non-stimulated STAT3, in the form of U-STAT3, has important 
genomic functions that are not well understood. In the heart, 
U-STAT3 may upregulate a specific sets of genes independently 
or via interaction with other transcription factors such as NF-κB, 
sustaining presumably an inflammatory and pro-hypertrophic 
effect. U-STAT3 may function as well in chromatin organiza-
tion and assembly. While there is growing consensus for the 
importance of a non-genomic role of STAT3 in mitochondria, 
the molecular basis by which STAT3 modulates ETC activity 
and ROS production is not known, nor how that may affect 
mitochondrial redox status. All these actions of STAT3 raise a 
question as how to target it therapeutically to favor its beneficial 
actions in order to prevent or reverse adverse cardiac remodeling. 
Further investigation into how STAT3 is regulated is crucial to 
achieving this goal.
AUTHOR CONTRiBUTiONS
All authors contributed conceptually to the manuscript. All 
authors authored sections of the manuscript, contributed to the 
figure design, and approved the final version.
November 2015 | Volume 2 | Article 3613
Zouein et al. Protective Role of Myocardial STAT3
Frontiers in Cardiovascular Medicine | www.frontiersin.org
ACKNOwLeDGMeNTS
The authors acknowledge the contribution of Mr. Venkata Ramana 
Vaka to the paragraph on the A/D transition of complex I.
FUNDiNG
This work was supported by a grant (100410) from the 
American University of Beirut (FAZ), a Merit Review Award 
(1IO1BX001355-0A1) from the Office of Research and 
Development, Medical Research Service, U.S. Department of 
Veterans Affairs (EJL), the CCTR Endowment Fund of the 
Virginia Commonwealth University and Virginia Commonwealth 
University CTSA (UL1TR000058 from the NIH National 
Center for Advancing Translational Science) (QC), a Scientist 
Development Grant from the American Heart Association (QC), 
the Pauley Heart Center of Virginia Commonwealth University 
(QC, EJL), the University of Mississippi Medical Center 
Department of Pharmacology and Toxicology (RA, GWB), and a 
grant from the Lebanese University (MK).
ReFeReNCeS
1. Zouein FA, Kurdi M, Booz GW. Dancing rhinos in stilettos: the amazing saga 
of the genomic and nongenomic actions of STAT3 in the heart. JAKSTAT 
(2013) 2:e24352. doi:10.4161/jkst.24352 
2. Kurdi M, Booz GW. JAK redux: a second look at the regulation and role of 
JAKs in the heart. Am J Physiol Heart Circ Physiol (2009) 297:H1545–56. 
doi:10.1152/ajpheart.00032.2009 
3. Kurdi M, Booz GW. Can the protective actions of JAK-STAT in the heart 
be exploited therapeutically? Parsing the regulation of interleukin-6-type 
cytokine signaling. J Cardiovasc Pharmacol (2007) 50:126–41. doi:10.1097/
FJC.0b013e318068dd49 
4. Szczepanek K, Lesnefsky EJ, Larner AC. Multi-tasking: nuclear transcrip-
tion factors with novel roles in the mitochondria. Trends Cell Biol (2012) 
22:429–37. doi:10.1016/j.tcb.2012.05.001 
5. Szczepanek K, Chen Q, Larner AC, Lesnefsky EJ. Cytoprotection by the 
modulation of mitochondrial electron transport chain: the emerging role 
of mitochondrial STAT3. Mitochondrion (2012) 12:180–9. doi:10.1016/j.
mito.2011.08.011 
6. Das A, Salloum FN, Filippone SM, Durrant DE, Rokosh G, Bolli R, et  al. 
Inhibition of mammalian target of rapamycin protects against reperfusion 
injury in diabetic heart through STAT3 signaling. Basic Res Cardiol (2015) 
110:31. doi:10.1007/s00395-015-0486-5 
7. Drenger B, Ostrovsky IA, Barak M, Nechemia-Arbely Y, Ziv E, Axelrod 
JH. Diabetes blockade of sevoflurane postconditioning is not restored by 
insulin in the rat heart: phosphorylated signal transducer and activator of 
transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. 
Anesthesiology (2011) 114:1364–72. doi:10.1097/ALN.0b013e31820efafd 
8. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch 
G, et  al. Cardioprotection by ischemic postconditioning is lost in aged 
and STAT3-deficient mice. Circ Res (2008) 102:131–5. doi:10.1161/
CIRCRESAHA.107.164699 
9. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocar-
dial JAK/STAT pathway: from protection to failure. Pharmacol Ther (2008) 
120:172–85. doi:10.1016/j.pharmthera.2008.08.002 
10. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg 
A, Wollert KC, et  al. Alterations in Janus kinase (JAK)-signal transducers 
and activators of transcription (STAT) signaling in patients with end-stage 
dilated cardiomyopathy. Circulation (2003) 107:798–802. doi:10.1161/01.
CIR.0000057545.82749.FF 
11. Cambi GE, Lucchese G, Djeokeng MM, Modesti A, Fiaschi T, Faggian G, et al. 
Impaired JAK2-induced activation of STAT3 in failing human myocytes. Mol 
Biosyst (2012) 8:2351–9. doi:10.1039/c2mb25120e 
12. Shi T, Papay RS, Perez DM. Alpha1a-adrenergic receptor differentially regu-
lates STAT3 phosphorylation through PKCЄ and PKCδ in myocytes. J Recept 
Signal Transduct Res (2012) 32:76–86. doi:10.3109/10799893.2011.647353 
13. Willey CD, Palanisamy AP, Johnston RK, Mani SK, Shiraishi H, Tuxworth 
WJ, et al. STAT3 activation in pressure-overloaded feline myocardium: role 
for integrins and the tyrosine kinase BMX. Int J Biol Sci (2008) 4:184–99. 
doi:10.7150/ijbs.4.184 
14. Frias MA, James RW, Gerber-Wicht C, Lang U. Native and reconstituted 
HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of 
sphingosine-1-phosphate. Cardiovasc Res (2009) 82:313–23. doi:10.1093/
cvr/cvp024 
15. Wu G, Liu Y, Huang H, Tang Y, Liu W, Mei Y, et  al. SH2B1 is critical for 
the regulation of cardiac remodelling in response to pressure overload. 
Cardiovasc Res (2015) 107:203–15. doi:10.1093/cvr/cvv170 
16. Matsui H, Yokoyama T, Tanaka C, Sunaga H, Koitabashi N, Takizawa T, et al. 
Pressure mediated hypertrophy and mechanical stretch up-regulate expres-
sion of the long form of leptin receptor (ob-Rb) in rat cardiac myocytes. BMC 
Cell Biol (2012) 13:37. doi:10.1186/1471-2121-13-37 
17. Qiu H, Lizano P, Laure L, Sui X, Rashed E, Park JY, et  al. H11 kinase/
heat shock protein 22 deletion impairs both nuclear and mitochondrial 
functions of STAT3 and accelerates the transition into heart failure 
on cardiac overload. Circulation (2011) 124:406–15. doi:10.1161/
CIRCULATIONAHA.110.013847 
18. Miyamoto T, Takeishi Y, Takahashi H, Shishido T, Arimoto T, Tomoike H, 
et al. Activation of distinct signal transduction pathways in hypertrophied 
hearts by pressure and volume overload. Basic Res Cardiol (2004) 99:328–37. 
doi:10.1007/s00395-004-0482-7 
19. Uozumi H, Hiroi Y, Zou Y, Takimoto E, Toko H, Niu P, et al. gp130 plays a 
critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 
(2001) 276:23115–9. doi:10.1074/jbc.M100814200 
20. Pan J, Fukuda K, Kodama H, Sano M, Takahashi T, Makino S, et  al. 
Involvement of gp130-mediated signaling in pressure overload-induced 
activation of the JAK/STAT pathway in rodent heart. Heart Vessels (1998) 
13:199–208. doi:10.1007/BF01745045 
21. Pan J, Fukuda K, Saito M, Matsuzaki J, Kodama H, Sano M, et al. Mechanical 
stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 
(1999) 84:1127–36. doi:10.1161/01.RES.84.10.1127 
22. Pan J, Fukuda K, Kodama H, Makino S, Takahashi T, Sano M, et  al. Role 
of angiotensin II in activation of the JAK/STAT pathway induced by acute 
pressure overload in the rat heart. Circ Res (1997) 81:611–7. doi:10.1161/01.
RES.81.4.611 
23. Booz GW, Day JN, Baker KM. Interplay between the cardiac renin 
angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, 
ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol (2002) 
34:1443–53. doi:10.1006/jmcc.2002.2076 
24. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, et al. Interleukin-6 
family of cytokines mediate angiotensin II-induced cardiac hypertrophy in 
rodent cardiomyocytes. J Biol Chem (2000) 275:29717–23. doi:10.1074/jbc.
M003128200 
25. Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, et al. Angiotensin 
II activates signal transducer and activators of transcription 3 via Rac1 in 
atrial myocytes and fibroblasts: implication for the therapeutic effect of statin 
in atrial structural remodeling. Circulation (2008) 117:344–55. doi:10.1161/
CIRCULATIONAHA.107.695346 
26. Zouein FA, Zgheib C, Hamza S, Fuseler JW, Hall JE, Soljancic A, et al. Role 
of STAT3 in angiotensin II-induced hypertension and cardiac remodeling 
revealed by mice lacking STAT3 serine 727 phosphorylation. Hypertens Res 
(2013) 36:496–503. doi:10.1038/hr.2012.223 
27. Iwasaki H, Kovacic JC, Olive M, Beers JK, Yoshimoto T, Crook MF, et  al. 
Disruption of protein arginine N-methyltransferase 2 regulates leptin signal-
ing and produces leanness in vivo through loss of STAT3 methylation. Circ 
Res (2010) 107:992–1001. doi:10.1161/CIRCRESAHA.110.225326 
28. Dasgupta M, Dermawan JK, Willard B, Stark GR. STAT3-driven transcrip-
tion depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci U 
S A (2015) 112:3985–90. doi:10.1073/pnas.1503152112 
November 2015 | Volume 2 | Article 3614
Zouein et al. Protective Role of Myocardial STAT3
Frontiers in Cardiovascular Medicine | www.frontiersin.org
29. Ray S, Boldogh I, Brasier AR. STAT3 NH2-terminal acetylation is activated 
by the hepatic acute-phase response and required for IL-6 induction of 
angiotensinogen. Gastroenterology (2005) 129:1616–32. doi:10.1053/j.
gastro.2005.07.055 
30. Hou T, Ray S, Lee C, Brasier AR. The STAT3 NH2-terminal domain stabilizes 
enhanceosome assembly by interacting with the p300 bromodomain. J Biol 
Chem (2008) 283:30725–34. doi:10.1074/jbc.M805941200 
31. Ray S, Lee C, Hou T, Boldogh I, Brasier AR. Requirement of histone deacety-
lase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) 
nucleocytoplasmic distribution. Nucleic Acids Res (2008) 36:4510–20. 
doi:10.1093/nar/gkn419 
32. Icardi L, Mori R, Gesellchen V, Eyckerman S, De Cauwer L, Verhelst J, et al. 
The Sin3a repressor complex is a master regulator of STAT transcriptional 
activity. Proc Natl Acad Sci U S A (2012) 109:12058–63. doi:10.1073/
pnas.1206458109 
33. Ray S, Zhao Y, Jamaluddin M, Edeh CB, Lee C, Brasier AR. Inducible 
STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex for-
mation to regulate apoptosis. Cell Signal (2014) 26:1445–55. doi:10.1016/j.
cellsig.2014.03.007 
34. Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, et al. Reversible 
methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc 
Natl Acad Sci U S A (2010) 107:21499–504. doi:10.1073/pnas.1016147107 
35. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation 
of EZH2 activates STAT3 signaling via STAT3 methylation and promotes 
tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 23:839–52. 
doi:10.1016/j.ccr.2013.04.008 
36. Kim J, Won JS, Singh AK, Sharma AK, Singh I. STAT3 regulation by 
S-nitrosylation: implication for inflammatory disease. Antioxid Redox Signal 
(2014) 20:2514–27. doi:10.1089/ars.2013.5223 
37. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, et al. STAT3 
inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol (2009) 
11:492–500. doi:10.1038/ncb1857 
38. Ray S, Sherman CT, Lu M, Brasier AR. Angiotensinogen gene expression is 
dependent on signal transducer and activator of transcription 3-mediated 
p300/cAMP response element binding protein-binding protein coactivator 
recruitment and histone acetyltransferase activity. Mol Endocrinol (2002) 
16:824–36. doi:10.1210/mend.16.4.0811 
39. Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA bind-
ing and transcription by p300/CREB-binding protein-mediated acetylation. J 
Biol Chem (2005) 280:11528–34. doi:10.1074/jbc.M413930200 
40. Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et  al. Acetylated 
STAT3 is crucial for methylation of tumor-suppressor gene promoters and 
inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A 
(2012) 109:7765–9. doi:10.1073/pnas.1205132109 
41. Thomas NS. The STAT3-DNMT1 connection. JAKSTAT (2012) 1:257–60. 
doi:10.4161/jkst.22436 
42. Dasgupta M, Unal H, Willard B, Yang J, Karnik SS, Stark GR. Critical role 
for lysine 685 in gene expression mediated by transcription factor unphos-
phorylated STAT3. J Biol Chem (2014) 289:30763–71. doi:10.1074/jbc.
M114.603894 
43. Waitkus MS, Chandrasekharan UM, Willard B, Tee TL, Hsieh JK, Przybycin 
CG, et al. Signal integration and gene induction by a functionally distinct 
STAT3 phosphoform. Mol Cell Biol (2014) 34:1800–11. doi:10.1128/
MCB.00034-14 
44. Schuringa JJ, Schepers H, Vellenga E, Kruijer W. Ser727-dependent transcrip-
tional activation by association of p300 with STAT3 upon IL-6 stimulation. 
FEBS Lett (2001) 495:71–6. doi:10.1016/S0014-5793(01)02354-7 
45. Tammineni P, Anugula C, Mohammed F, Anjaneyulu M, Larner AC, Sepuri 
NB. The import of the transcription factor STAT3 into mitochondria depends 
on GRIM-19, a component of the electron transport chain. J Biol Chem 
(2013) 288:4723–32. doi:10.1074/jbc.M112.378984 
46. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, et al. Function 
of mitochondrial Stat3 in cellular respiration. Science (2009) 323:793–7. 
doi:10.1126/science.1164551 
47. Gough DJ, Koetz L, Levy DE. The MEK-ERK pathway is necessary for serine 
phosphorylation of mitochondrial STAT3 and Ras-mediated transformation. 
PLoS One (2013) 8:e83395. doi:10.1371/journal.pone.0083395 
48. Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, 
et  al. Mitochondrial localized Stat3 promotes breast cancer growth via 
phosphorylation of serine 727. J Biol Chem (2013) 288:31280–8. doi:10.1074/
jbc.M113.505057 
49. Booz GW, Day JN, Baker KM. Angiotensin II effects on STAT3 phos-
phorylation in cardiomyocytes: evidence for Erk-dependent Tyr705 
dephosphorylation. Basic Res Cardiol (2003) 98:33–8. doi:10.1007/
s00395-003-0387-x 
50. Ng IH, Bogoyevitch MA, Jans DA. Cytokine-induced slowing of STAT3 
nuclear import; faster basal trafficking of the STAT3β isoform. Traffic (2014) 
15:946–60. doi:10.1111/tra.12181 
51. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF, et al. The cell death 
regulator GRIM-19 is an inhibitor of signal transducer and activator of 
transcription 3. Proc Natl Acad Sci U S A (2003) 100:9342–7. doi:10.1073/
pnas.1633516100 
52. O’Shea JJ, Kanno Y, Chen X, Levy DE. Cell signaling. Stat acetylation – a 
key facet of cytokine signaling? Science (2005) 307:217–8. doi:10.1126/
science.1108164 
53. Stark GR, Wang Y, Lu T. Lysine methylation of promoter-bound transcription 
factors and relevance to cancer. Cell Res (2011) 21:375–80. doi:10.1038/
cr.2010.174 
54. Komyod W, Bauer UM, Heinrich PC, Haan S, Behrmann I. Are STATS 
arginine-methylated? J Biol Chem (2005) 280:21700–5. doi:10.1074/jbc.
C400606200 
55. Xie Y, Kole S, Precht P, Pazin MJ, Bernier M. S-glutathionylation impairs 
signal transducer and activator of transcription 3 activation and signaling. 
Endocrinology (2009) 150:1122–31. doi:10.1210/en.2008-1241 
56. Butturini E, Darra E, Chiavegato G, Cellini B, Cozzolino F, Monti M, et al. 
S-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation. 
ACS Chem Biol (2014) 9:1885–93. doi:10.1021/cb500407d 
57. Li L, Shaw PE. A STAT3 dimer formed by inter-chain disulphide bridging 
during oxidative stress. Biochem Biophys Res Commun (2004) 322:1005–11. 
doi:10.1016/j.bbrc.2004.08.014 
58. Sobotta MC, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, et  al. 
Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat Chem 
Biol (2015) 11:64–70. doi:10.1038/nchembio.1695 
59. Li L, Cheung SH, Evans EL, Shaw PE. Modulation of gene expression and 
tumor cell growth by redox modification of STAT3. Cancer Res (2010) 
70:8222–32. doi:10.1158/0008-5472.CAN-10-0894 
60. Kurdi M, Sivakumaran V, Duhe RJ, Aon MA, Paolocci N, Booz GW. Depletion 
of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in 
cardiac myocytes. Int J Biochem Cell Biol (2012) 44:2106–15. doi:10.1016/j.
biocel.2012.08.016 
61. Zgheib C, Kurdi M, Zouein FA, Gunter BW, Stanley BA, Zgheib J, et  al. 
Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and 
cardiac myocytes: evidence that STAT3 signaling is redox-sensitive. PLoS 
One (2012) 7:e43313. doi:10.1371/journal.pone.0043313 
62. Zouein FA, Kurdi M, Booz GW. LIF and the heart: just another brick in the 
wall? Eur Cytokine Netw (2013) 24:11–9. doi:10.1684/ecn.2013.0335 
63. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, et al. Genetic 
depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. 
Cardiovasc Res (2004) 63:611–6. doi:10.1016/j.cardiores.2004.06.019 
64. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, 
et al. Signal transducer and activator of transcription 3 is required for myo-
cardial capillary growth, control of interstitial matrix deposition, and heart 
protection from ischemic injury. Circ Res (2004) 95:187–95. doi:10.1161/01.
RES.0000134921.50377.61 
65. Hilfiker-Kleiner D, Limbourg A, Drexler H. STAT3-mediated activation 
of myocardial capillary growth. Trends Cardiovasc Med (2005) 15:152–7. 
doi:10.1016/j.tcm.2005.05.002 
66. Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, et  al. 
Cardiac-specific activation of signal transducer and activator of transcription 
3 promotes vascular formation in the heart. J Biol Chem (2002) 277:6676–81. 
doi:10.1074/jbc.M108246200 
67. Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, et al. Signal 
transducer and activator of transcription 3 is required for glycoprotein 
130-mediated induction of vascular endothelial growth factor in cardiac 
myocytes. J Biol Chem (2000) 275:10561–6. doi:10.1074/jbc.275.14.10561 
68. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, et al. 
Activation of signal transducer and activator of transcription 3 protects car-
diomyocytes from hypoxia/reoxygenation-induced oxidative stress through 
November 2015 | Volume 2 | Article 3615
Zouein et al. Protective Role of Myocardial STAT3
Frontiers in Cardiovascular Medicine | www.frontiersin.org
the upregulation of manganese superoxide dismutase. Circulation (2001) 
104:979–81. doi:10.1161/hc3401.095947 
69. Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, Dawn B, et  al. A murine 
model of inducible, cardiac-specific deletion of STAT3: its use to determine 
the role of STAT3 in the upregulation of cardioprotective proteins by isch-
emic preconditioning. J Mol Cell Cardiol (2011) 50:589–97. doi:10.1016/j.
yjmcc.2011.01.002 
70. Enomoto D, Obana M, Miyawaki A, Maeda M, Nakayama H, Fujio Y. 
Cardiac-specific ablation of the STAT3 gene in the subacute phase of myo-
cardial infarction exacerbated cardiac remodeling. Am J Physiol Heart Circ 
Physiol (2015) 309:H471–80. doi:10.1152/ajpheart.00730.2014 
71. Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, Gabrielson KL, et al. 
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamox-
ifen-induced MerCreMer gene deletion models. Circ Res (2009) 105:12–5. 
doi:10.1161/CIRCRESAHA.109.198416 
72. Oba T, Yasukawa H, Hoshijima M, Sasaki K, Futamata N, Fukui D, et  al. 
Cardiac-specific deletion of SOCS-3 prevents development of left ventric-
ular remodeling after acute myocardial infarction. J Am Coll Cardiol (2012) 
59:838–52. doi:10.1016/j.jacc.2011.10.887 
73. Nagata T, Yasukawa H, Kyogoku S, Oba T, Takahashi J, Nohara S, et  al. 
Cardiac-specific SOCS3 deletion prevents in  vivo myocardial ischemia 
reperfusion injury through sustained activation of cardioprotective signaling 
molecules. PLoS One (2015) 10:e0127942. doi:10.1371/journal.pone.0127942 
74. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, et al. 
Continuous glycoprotein-130-mediated signal transducer and activator of 
transcription-3 activation promotes inflammation, left ventricular rupture, 
and adverse outcome in subacute myocardial infarction. Circulation (2010) 
122:145–55. doi:10.1161/CIRCULATIONAHA.109.933127 
75. Zgheib C, Zouein FA, Kurdi M, Booz GW. Differential STAT3 signaling in 
the heart: impact of concurrent signals and oxidative stress. JAKSTAT (2012) 
1:101–10. doi:10.4161/jkst.19776 
76. Heusch G. Molecular basis of cardioprotection: signal transduction in 
ischemic pre-, post-, and remote conditioning. Circ Res (2015) 116:674–99. 
doi:10.1161/CIRCRESAHA.116.305348 
77. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: a role 
for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 
(2008) 295:H1649–56. doi:10.1152/ajpheart.00692.2008 
78. Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, 
et al. Signal transducer and activator of transcription 3 is involved in the car-
dioprotective signalling pathway activated by insulin therapy at reperfusion. 
Basic Res Cardiol (2008) 103:444–53. doi:10.1007/s00395-008-0728-x 
79. Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G. 
Across-species transfer of protection by remote ischemic preconditioning 
with species-specific myocardial signal transduction by reperfusion injury 
salvage kinase and survival activating factor enhancement pathways. Circ Res 
(2015) 117:279–88. doi:10.1161/CIRCRESAHA.117.306878 
80. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M. STAT5 
activation and cardioprotection by remote ischemic preconditioning in 
humans: short communication. Circ Res (2012) 110:111–5. doi:10.1161/
CIRCRESAHA.111.259556 
81. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between SAFE 
and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. 
Cardiovasc Drugs Ther (2012) 26:227–37. doi:10.1007/s10557-012-6376-2 
82. Cai ZP, Parajuli N, Zheng X, Becker L. Remote ischemic preconditioning 
confers late protection against myocardial ischemia-reperfusion injury 
in mice by upregulating interleukin-10. Basic Res Cardiol (2012) 107:277. 
doi:10.1007/s00395-012-0277-1 
83. Cai WF, Kang K, Huang W, Liang JL, Feng YL, Liu GS, et al. CXCR4 attenuates 
cardiomyocytes mitochondrial dysfunction to resist ischaemia-reperfusion 
injury. J Cell Mol Med (2015) 19:1825–35. doi:10.1111/jcmm.12554 
84. Nishinakamura H, Minoda Y, Saeki K, Koga K, Takaesu G, Onodera M, 
et  al. An RNA-binding protein αCP-1 is involved in the STAT3-mediated 
suppression of NF-κB transcriptional activity. Int Immunol (2007) 19:609–19. 
doi:10.1093/intimm/dxm026 
85. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, 
et  al. Pharmacological preconditioning with tumor necrosis factor-alpha 
activates signal transducer and activator of transcription-3 at reperfusion 
without involving classic prosurvival kinases (Akt and extracellular 
signal-regulated kinase). Circulation (2005) 112:3911–8. doi:10.1161/
CIRCULATIONAHA.105.581058 
86. Miura T, Tanno M. The mPTP and its regulatory proteins: final common 
targets of signalling pathways for protection against necrosis. Cardiovasc Res 
(2012) 94:181–9. doi:10.1093/cvr/cvr302 
87. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of per-
meability transition pore opening by mitochondrial STAT3 and its role in 
myocardial ischemia/reperfusion. Basic Res Cardiol (2010) 105:771–85. 
doi:10.1007/s00395-010-0124-1 
88. Szczepanek K, Chen Q, Derecka M, Salloum FN, Zhang Q, Szelag M, et al. 
Mitochondrial-targeted signal transducer and activator of transcription 3 
(STAT3) protects against ischemia-induced changes in the electron trans-
port chain and the generation of reactive oxygen species. J Biol Chem (2011) 
286:29610–20. doi:10.1074/jbc.M111.226209 
89. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activa-
tion and cardioprotection by ischemic postconditioning in pigs with regional 
myocardial ischemia/reperfusion. Circ Res (2011) 109:1302–8. doi:10.1161/
CIRCRESAHA.111.255604 
90. Li J, Umar S, Iorga A, Youn JY, Wang Y, Regitz-Zagrosek V, et al. Cardiac 
vulnerability to ischemia/reperfusion injury drastically increases in late preg-
nancy. Basic Res Cardiol (2012) 107:271. doi:10.1007/s00395-012-0271-7 
91. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, 
Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates 
postpartum cardiomyopathy. Cell (2007) 128:589–600. doi:10.1016/j.
cell.2006.12.036 
92. Ricke-Hoch M, Bultmann I, Stapel B, Condorelli G, Rinas U, Sliwa K, et al. 
Opposing roles of Akt and STAT3 in the protection of the maternal heart 
from peripartum stress. Cardiovasc Res (2014) 101:587–96. doi:10.1093/cvr/
cvu010 
93. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner 
D, Bollen IA, Sliwa K, et al. Titin gene mutations are common in families with 
both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J 
(2014) 35:2165–73. doi:10.1093/eurheartj/ehu050 
94. Haghikia A, Missol-Kolka E, Tsikas D, Venturini L, Brundiers S, Castoldi M, 
et al. Signal transducer and activator of transcription 3-mediated regulation 
of miR-199a-5p links cardiomyocyte and endothelial cell function in the 
heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J (2011) 
32:1287–97. doi:10.1093/eurheartj/ehq369 
95. Verma SK, Krishnamurthy P, Barefield D, Singh N, Gupta R, Lambers 
E, et  al. Interleukin-10 treatment attenuates pressure overload-induced 
hypertrophic remodeling and improves heart function via signal 
transducers and activators of transcription 3-dependent inhibition of 
nuclear factor-κB. Circulation (2012) 126:418–29. doi:10.1161/
CIRCULATIONAHA.112.112185 
96. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators 
of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine 
Res (2011) 31:33–40. doi:10.1089/jir.2010.0100 
97. Yue H, Li W, Desnoyer R, Karnik SS. Role of nuclear unphosphorylated 
STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. 
Cardiovasc Res (2010) 85:90–9. doi:10.1093/cvr/cvp285 
98. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated 
STAT3 accumulates in response to IL-6 and activates transcription by binding 
to NFκB. Genes Dev (2007) 21:1396–408. doi:10.1101/gad.1553707 
99. Kurdi M, Booz GW. New take on the role of angiotensin II in cardiac 
hypertrophy and fibrosis. Hypertension (2011) 57:1034–8. doi:10.1161/
HYPERTENSIONAHA.111.172700 
100. Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, 
Tarasov SG, et  al. Mechanisms of unphosphorylated STAT3 transcription 
factor binding to DNA. J Biol Chem (2012) 287:14192–200. doi:10.1074/jbc.
M111.323899 
101. Yan SJ, Lim SJ, Shi S, Dutta P, Li WX. Unphosphorylated STAT and heteroch-
romatin protect genome stability. FASEB J (2011) 25:232–41. doi:10.1096/
fj.10-169367 
102. Shi S, Larson K, Guo D, Lim SJ, Dutta P, Yan SJ, et al. Drosophila STAT is 
required for directly maintaining HP1 localization and heterochromatin 
stability. Nat Cell Biol (2008) 10:489–96. doi:10.1038/ncb1713 
103. Xu N, Emelyanov AV, Fyodorov DV, Skoultchi AI. Drosophila linker 
histone H1 coordinates STAT-dependent organization of heterochromatin 
November 2015 | Volume 2 | Article 3616
Zouein et al. Protective Role of Myocardial STAT3
Frontiers in Cardiovascular Medicine | www.frontiersin.org
and suppresses tumorigenesis caused by hyperactive JAK-STAT signaling. 
Epigenetics Chromatin (2014) 7:16. doi:10.1186/1756-8935-7-16 
104. Hu X, Dutta P, Tsurumi A, Li J, Wang J, Land H, et al. Unphosphorylated 
STAT5A stabilizes heterochromatin and suppresses tumor growth. Proc Natl 
Acad Sci U S A (2013) 110:10213–8. doi:10.1073/pnas.1221243110 
105. Meyer T, Gavenis K, Vinkemeier U. Cell type-specific and tyrosine phos-
phorylation-independent nuclear presence of STAT1 and STAT3. Exp Cell 
Res (2002) 272:45–55. doi:10.1006/excr.2001.5405 
106. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of 
tyrosine phosphorylation and mediated by importin-α3. Proc Natl Acad Sci 
U S A (2005) 102:8150–5. doi:10.1073/pnas.0501643102 
107. Cimica V, Chen HC, Iyer JK, Reich NC. Dynamics of the STAT3 transcription 
factor: nuclear import dependent on Ran and importin-β1. PLoS One (2011) 
6:e20188. doi:10.1371/journal.pone.0020188 
108. Reich NC. STATs get their move on. JAKSTAT (2013) 2:e27080. doi:10.4161/
jkst.27080 
109. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 
(2008) 18:443–51. doi:10.1038/cr.2008.41 
110. Ushijima R, Sakaguchi N, Kano A, Maruyama A, Miyamoto Y, Sekimoto T, 
et al. Extracellular signal-dependent nuclear import of STAT3 is mediated by 
various importin alphas. Biochem Biophys Res Commun (2005) 330:880–6. 
doi:10.1016/j.bbrc.2005.03.063 
111. Ma J, Cao X. Regulation of Stat3 nuclear import by importin α5 and impor-
tin α7 via two different functional sequence elements. Cell Signal (2006) 
18:1117–26. doi:10.1016/j.cellsig.2005.06.016 
112. Ma J, Zhang T, Novotny-Diermayr V, Tan AL, Cao X. A novel sequence in the 
coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 
(2003) 278:29252–60. doi:10.1074/jbc.M304196200 
113. Vogt M, Domoszlai T, Kleshchanok D, Lehmann S, Schmitt A, Poli V, et al. 
The role of the N-terminal domain in dimerization and nucleocytoplasmic 
shuttling of latent STAT3. J Cell Sci (2011) 124:900–9. doi:10.1242/jcs.072520 
114. Sato N, Tsuruma R, Imoto S, Sekine Y, Muromoto R, Sugiyama K, et  al. 
Nuclear retention of STAT3 through the coiled-coil domain regulates its 
activity. Biochem Biophys Res Commun (2005) 336:617–24. doi:10.1016/j.
bbrc.2005.08.145 
115. Bhattacharya S, Schindler C. Regulation of Stat3 nuclear export. J Clin Invest 
(2003) 111:553–9. doi:10.1172/JCI15372 
116. Qi QR, Yang ZM. Regulation and function of signal transducer and activator 
of transcription 3. World J Biol Chem (2014) 5:231–9. doi:10.4331/wjbc.
v5.i2.231 
117. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of 
NF-κB p100 processing involves CBP/p300-mediated acetylation. Proc Natl 
Acad Sci U S A (2006) 103:7264–9. doi:10.1073/pnas.0509808103 
118. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently 
activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 
(2009) 15:283–93. doi:10.1016/j.ccr.2009.02.015 
119. Cavaillon JM. Pro- versus anti-inflammatory cytokines: myth or reality. Cell 
Mol Biol (Noisy-le-grand) (2001) 47:695–702. 
120. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. 
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. 
Science (2009) 324:1713–6. doi:10.1126/science.1171721 
121. Gough DJ, Marie IJ, Lobry C, Aifantis I, Levy DE. STAT3 supports experi-
mental K-RasG12D-induced murine myeloproliferative neoplasms depen-
dent on serine phosphorylation. Blood (2014) 124:2252–61. doi:10.1182/
blood-2013-02-484196 
122. Yu C, Huo X, Agoston AT, Zhang X, Theiss AL, Cheng E, et al. Mitochondrial 
STAT3 contributes to transformation of Barrett’s epithelial cells that express 
oncogenic Ras in a p53-independent fashion. Am J Physiol Gastrointest Liver 
Physiol (2015) 309:G146–61. doi:10.1152/ajpgi.00462.2014 
123. Phillips D, Reilley MJ, Aponte AM, Wang G, Boja E, Gucek M, et  al. 
Stoichiometry of STAT3 and mitochondrial proteins: implications for the 
regulation of oxidative phosphorylation by protein-protein interactions. J 
Biol Chem (2010) 285:23532–6. doi:10.1074/jbc.C110.152652 
124. Chen Q, Camara AK, Stowe DF, Hoppel CL, Lesnefsky EJ. Modulation of 
electron transport protects cardiac mitochondria and decreases myocardial 
injury during ischemia and reperfusion. Am J Physiol Cell Physiol (2007) 
292:C137–47. doi:10.1152/ajpcell.00270.2006 
125. Chen Q, Hoppel CL, Lesnefsky EJ. Blockade of electron transport before 
cardiac ischemia with the reversible inhibitor amobarbital protects rat 
heart mitochondria. J Pharmacol Exp Ther (2006) 316:200–7. doi:10.1124/
jpet.105.091702 
126. Schwarz K, Siddiqi N, Singh S, Neil CJ, Dawson DK, Frenneaux MP. The 
breathing heart  –  mitochondrial respiratory chain dysfunction in cardiac 
disease. Int J Cardiol (2014) 171:134–43. doi:10.1016/j.ijcard.2013.12.014 
127. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: impli-
cations beyond ATP production. Circ Res (2013) 113:709–24. doi:10.1161/
CIRCRESAHA.113.300376 
128. Rosca MG, Tandler B, Hoppel CL. Mitochondria in cardiac hypertrophy 
and heart failure. J Mol Cell Cardiol (2013) 55:31–41. doi:10.1016/j.
yjmcc.2012.09.002 
129. Osterholt M, Nguyen TD, Schwarzer M, Doenst T. Alterations in mitochon-
drial function in cardiac hypertrophy and heart failure. Heart Fail Rev (2013) 
18:645–56. doi:10.1007/s10741-012-9346-7 
130. Fontaine E, Bernardi P. Progress on the mitochondrial permeability transition 
pore: regulation by complex I and ubiquinone analogs. J Bioenerg Biomembr 
(1999) 31:335–45. doi:10.1023/A:1005475802350 
131. Koopman WJ, Nijtmans LG, Dieteren CE, Roestenberg P, Valsecchi F, 
Smeitink JA, et al. Mammalian mitochondrial complex I: biogenesis, regu-
lation, and reactive oxygen species generation. Antioxid Redox Signal (2010) 
12:1431–70. doi:10.1089/ars.2009.2743 
132. Chinopoulos C, Adam-Vizi V. Modulation of the mitochondrial perme-
ability transition by cyclophilin D: moving closer to F0-F1 ATP synthase? 
Mitochondrion (2012) 12:41–5. doi:10.1016/j.mito.2011.04.007 
133. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak 
W, Gong G, et  al. Mitochondrial complex I deficiency increases protein 
acetylation and accelerates heart failure. Cell Metab (2013) 18:239–50. 
doi:10.1016/j.cmet.2013.07.002 
134. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, 
et al. Exogenous NAD blocks cardiac hypertrophic response via activation 
of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem (2010) 
285:3133–44. doi:10.1074/jbc.M109.077271 
135. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, et al. A role for the 
mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl 
Acad Sci U S A (2008) 105:14447–52. doi:10.1073/pnas.0803790105 
136. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn 
C. Substrates and regulation mechanisms for the human mitochondrial 
sirtuins Sirt3 and Sirt5. J Mol Biol (2008) 382:790–801. doi:10.1016/j.
jmb.2008.07.048 
137. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, et al. Tumour suppressor 
SIRT3 deacetylates and activates manganese superoxide dismutase to scav-
enge ROS. EMBO Rep (2011) 12:534–41. doi:10.1038/embor.2011.65 
138. Yu W, Dittenhafer-Reed KE, Denu JM. SIRT3 protein deacetylates isocitrate 
dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol 
Chem (2012) 287:14078–86. doi:10.1074/jbc.M112.355206 
139. Zeng H, Vaka VR, He X, Booz GW, Chen JX. High-fat diet induces cardiac 
remodelling and dysfunction: assessment of the role played by SIRT3 loss. J 
Cell Mol Med (2015) 19:1847–56. doi:10.1111/jcmm.12556 
140. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. 
Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 
166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) (2010) 
2:914–23. 
141. Porter GA, Urciuoli WR, Brookes PS, Nadtochiy SM. SIRT3 deficiency 
exacerbates ischemia-reperfusion injury: implication for aged hearts. 
Am J Physiol Heart Circ Physiol (2014) 306:H1602–9. doi:10.1152/
ajpheart.00027.2014 
142. Parodi-Rullan R, Barreto-Torres G, Ruiz L, Casasnovas J, Javadov S. Direct 
renin inhibition exerts an anti-hypertrophic effect associated with improved 
mitochondrial function in post-infarction heart failure in diabetic rats. Cell 
Physiol Biochem (2012) 29:841–50. doi:10.1159/000178526 
143. Moreno-Lastres D, Fontanesi F, Garcia-Consuegra I, Martin MA, Arenas 
J, Barrientos A, et  al. Mitochondrial complex I plays an essential role in 
human respirasome assembly. Cell Metab (2012) 15:324–35. doi:10.1016/j.
cmet.2012.01.015 
144. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, et al. 
Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative 
phosphorylation. Cardiovasc Res (2008) 80:30–9. doi:10.1093/cvr/cvn184 
145. Rosca MG, Hoppel CL. Mitochondria in heart failure. Cardiovasc Res (2010) 
88:40–50. doi:10.1093/cvr/cvq240 
November 2015 | Volume 2 | Article 3617
Zouein et al. Protective Role of Myocardial STAT3
Frontiers in Cardiovascular Medicine | www.frontiersin.org
146. Miwa S, Jow H, Baty K, Johnson A, Czapiewski R, Saretzki G, et  al. Low 
abundance of the matrix arm of complex I in mitochondria predicts longevity 
in mice. Nat Commun (2014) 5:3837. doi:10.1038/ncomms4837 
147. Jonas EA, Porter GA Jr, Beutner G, Mnatsakanyan N, Alavian KN. Cell death 
disguised: the mitochondrial permeability transition pore as the c-subunit 
of the F1FO ATP synthase. Pharmacol Res (2015) 99:382–92. doi:10.1016/j.
phrs.2015.04.013 
148. Hirst J, Carroll J, Fearnley IM, Shannon RJ, Walker JE. The nuclear encoded 
subunits of complex I from bovine heart mitochondria. Biochim Biophys Acta 
(2003) 1604:135–50. doi:10.1016/S0005-2728(03)00059-8 
149. Carroll J, Fearnley IM, Shannon RJ, Hirst J, Walker JE. Analysis of the 
subunit composition of complex I from bovine heart mitochondria. Mol Cell 
Proteomics (2003) 2:117–26. doi:10.1074/mcp.M300014-MCP200 
150. Vinothkumar KR, Zhu J, Hirst J. Architecture of mammalian respiratory 
complex I. Nature (2014) 515:80–4. doi:10.1038/nature13686 
151. Lu H. The Study of GRIM-19 Function in Mitochondria. Ph.D., Institute of 
Molecular and Cell Biology, Agency for Science, Technology and Research, 
Singapore (2007).
152. Babot M, Labarbuta P, Birch A, Kee S, Fuszard M, Botting CH, et al. ND3, 
ND1 and 39kDa subunits are more exposed in the de-active form of bovine 
mitochondrial complex I. Biochim Biophys Acta (2014) 1837:929–39. 
doi:10.1016/j.bbabio.2014.02.013 
153. Tocilescu MA, Zickermann V, Zwicker K, Brandt U. Quinone binding and 
reduction by respiratory complex I. Biochim Biophys Acta (2010) 1797:1883–
90. doi:10.1016/j.bbabio.2010.05.009 
154. Baradaran R, Berrisford JM, Minhas GS, Sazanov LA. Crystal structure of 
the entire respiratory complex I. Nature (2013) 494:443–8. doi:10.1038/
nature11871 
155. Efremov RG, Baradaran R, Sazanov LA. The architecture of respiratory 
complex I. Nature (2010) 465:441–5. doi:10.1038/nature09066 
156. Angerer H, Nasiri HR, Niedergesass V, Kerscher S, Schwalbe H, Brandt U. 
Tracing the tail of ubiquinone in mitochondrial complex I. Biochim Biophys 
Acta (2012) 1817:1776–84. doi:10.1016/j.bbabio.2012.03.021 
157. Chen YR, Zweier JL. Cardiac mitochondria and reactive oxygen species gen-
eration. Circ Res (2014) 114:524–37. doi:10.1161/CIRCRESAHA.114.300559 
158. Chen Q, Moghaddas S, Hoppel CL, Lesnefsky EJ. Ischemic defects in the elec-
tron transport chain increase the production of reactive oxygen species from 
isolated rat heart mitochondria. Am J Physiol Cell Physiol (2008) 294:C460–6. 
doi:10.1152/ajpcell.00211.2007 
159. Lu H, Cao X. GRIM-19 is essential for maintenance of mitochondrial 
membrane potential. Mol Biol Cell (2008) 19:1893–902. doi:10.1091/mbc.
E07-07-0683 
160. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, et  al. GRIM-19, a 
cell death regulatory protein, is essential for assembly and function of 
mitochondrial complex I. Mol Cell Biol (2004) 24:8447–56. doi:10.1128/
MCB.24.19.8447-8456.2004 
161. Palmisano G, Sardanelli AM, Signorile A, Papa S, Larsen MR. The phos-
phorylation pattern of bovine heart complex I subunits. Proteomics (2007) 
7:1575–83. doi:10.1002/pmic.200600801 
162. Morais VA, Haddad D, Craessaerts K, De Bock PJ, Swerts J, Vilain S, et al. 
PINK1 loss-of-function mutations affect mitochondrial complex I activity 
via NdufA10 ubiquinone uncoupling. Science (2014) 344:203–7. doi:10.1126/
science.1249161 
163. Drose S, Brandt U, Wittig I. Mitochondrial respiratory chain complexes as 
sources and targets of thiol-based redox-regulation. Biochim Biophys Acta 
(2014) 1844:1344–54. doi:10.1016/j.bbapap.2014.02.006 
164. Babot M, Galkin A. Molecular mechanism and physiological role of 
active-deactive transition of mitochondrial complex I. Biochem Soc Trans 
(2013) 41:1325–30. doi:10.1042/BST20130088 
165. Babot M, Birch A, Labarbuta P, Galkin A. Characterisation of the active/
de-active transition of mitochondrial complex I. Biochim Biophys Acta (2014) 
1837:1083–92. doi:10.1016/j.bbabio.2014.02.018 
166. Ciano M, Fuszard M, Heide H, Botting CH, Galkin A. Conformation-specific 
crosslinking of mitochondrial complex I. FEBS Lett (2013) 587:867–72. 
doi:10.1016/j.febslet.2013.02.039 
167. Galkin A, Moncada S. S-nitrosation of mitochondrial complex I depends on 
its structural conformation. J Biol Chem (2007) 282:37448–53. doi:10.1074/
jbc.M707543200 
168. Chouchani ET, Methner C, Nadtochiy SM, Logan A, Pell VR, Ding S, et al. 
Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial 
complex I. Nat Med (2013) 19:753–9. doi:10.1038/nm.3212 
169. Gorenkova N, Robinson E, Grieve DJ, Galkin A. Conformational change of 
mitochondrial complex I increases ROS sensitivity during ischemia. Antioxid 
Redox Signal (2013) 19:1459–68. doi:10.1089/ars.2012.4698 
170. Han J, Yu C, Souza RF, Theiss AL. Prohibitin 1 modulates mitochondrial func-
tion of Stat3. Cell Signal (2014) 26:2086–95. doi:10.1016/j.cellsig.2014.06.006 
171. Yang R, Lirussi D, Thornton TM, Jelley-Gibbs DM, Diehl SA, Case LK, et al. 
Mitochondrial Ca2+ and membrane potential, an alternative pathway for 
Interleukin 6 to regulate CD4 cell effector function. Elife (2015) 4:e06376. 
doi:10.7554/eLife.06376
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Zouein, Altara, Chen, Lesnefsky, Kurdi and Booz. This is 
an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
